1
|
Barnes EL, Dunn MS, Ashburn J, Barto A, Bloomfeld R, Cairns A, Mehta K, Patel P, Dziwis J, Esckilsen S, Rahbar R, Sadiq TS, Hanson JS, Herfarth HH. Extraintestinal Manifestations and Family History of Inflammatory Bowel Disease Increase the Risk of Pouchitis in a State-Level Epidemiology Study. Clin Transl Gastroenterol 2024; 15:e00670. [PMID: 38146854 PMCID: PMC10887435 DOI: 10.14309/ctg.0000000000000670] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 08/25/2023] [Accepted: 12/14/2023] [Indexed: 12/27/2023] Open
Abstract
INTRODUCTION Our understanding of the epidemiology of inflammatory conditions of the pouch and effectiveness of treatment is largely based on selected populations. We created a state-level registry to evaluate the incidence of pouchitis and the effectiveness of treatments used in an initial episode of pouchitis. METHODS In a state-level retrospective cohort of all patients undergoing proctocolectomy with ileal pouch-anal anastomosis (IPAA) for ulcerative colitis between January 1, 2018, and December 31, 2020, we evaluated the incidence of pouchitis and compared the proportion of patients developing recurrent pouchitis and chronic antibiotic-dependent pouchitis according to initial antibiotic therapy. RESULTS A total of 177 patients underwent surgery with 49 (28%) developing pouchitis within the 12 months after the final stage of IPAA. Patients with extraintestinal manifestations of inflammatory bowel disease (IBD) were significantly more likely to develop pouchitis within the first 12 months after IPAA (adjusted odds ratio 2.45, 95% confidence interval 1.03-5.81) after adjusting for family history of IBD (adjusted odds ratio 3.50, 95% 1.50-8.18). When comparing the proportion of patients who developed recurrent pouchitis or chronic antibiotic-dependent pouchitis with those who experienced an isolated episode of pouchitis, there were no significant differences among the initial antibiotic regimens used. DISCUSSION In a state-level examination of outcomes after IPAA for ulcerative colitis, patients with extraintestinal manifestations of IBD were more likely to develop pouchitis; however, the initial antibiotic regimen chosen did not seem to affect long-term outcomes.
Collapse
Affiliation(s)
- Edward L. Barnes
- Division of Gastroenterology and Hepatology, University of North Carolina, Chapel Hill, North Carolina, USA
- Center for Gastrointestinal Biology and Disease, University of North Carolina, Chapel Hill, North Carolina, USA
| | - Michael S. Dunn
- Department of Medicine, University of North Carolina, Chapel Hill, North Carolina, USA
| | - Jean Ashburn
- Division of Colon and Rectal Surgery, Atrium Health at Wake Forest Baptist, Winston-Salem, North Carolina, USA
| | - Amy Barto
- Division of Gastroenterology and Hepatology, Duke University, Durham, North Carolina, USA
| | - Richard Bloomfeld
- Section of Gastroenterology, Atrium Health at Wake Forest Baptist, Winston-Salem, North Carolina, USA
| | - Ashley Cairns
- Division of Colon and Rectal Surgery, Atrium Health at Wake Forest Baptist, Winston-Salem, North Carolina, USA
| | - Kurren Mehta
- Department of Medicine, Duke University, Durham, North Carolina, USA
| | - Pooja Patel
- Department of Medicine, Duke University, Durham, North Carolina, USA
| | - Jennifer Dziwis
- Section of Gastroenterology, Atrium Health at Wake Forest Baptist, Winston-Salem, North Carolina, USA
- Department of Medicine, Duke University, Durham, North Carolina, USA
| | - Scott Esckilsen
- University of North Carolina School of Medicine, Chapel Hill, North Carolina, USA
| | - Reza Rahbar
- North Carolina Surgery, Raleigh, North Carolina, USA
| | | | - John S. Hanson
- Division of Gastroenterology and Hepatology, Atrium Health, Charlotte, North Carolina, USA
| | - Hans H. Herfarth
- Division of Gastroenterology and Hepatology, University of North Carolina, Chapel Hill, North Carolina, USA
- Center for Gastrointestinal Biology and Disease, University of North Carolina, Chapel Hill, North Carolina, USA
| |
Collapse
|
2
|
Patel J, Wong N, Mehta K, Patel A. Gastroesophageal Reflux Disease. Prim Care 2023; 50:339-350. [PMID: 37516506 DOI: 10.1016/j.pop.2023.03.002] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 07/31/2023]
Abstract
Symptoms potentially attributable to gastroesophageal reflux disease are among those most commonly reported to primary care providers in the outpatient setting. In this review, we discuss clinical approaches to the evaluation and management of these symptoms, including proton pump inhibitor trials as well as specific indications or clinical settings that warrant referral to Gastroenterology specialists.
Collapse
Affiliation(s)
- Janaki Patel
- Department of Medicine, Ohio State University College of Medicine, 410 West 10th Avenue, Columbus, OH 43210, USA
| | - Natalie Wong
- Division of Gastroenterology, Duke University School of Medicine, Duke University Medical Center, Box 3913, Durham, NC 27710, USA
| | - Kurren Mehta
- Department of Medicine, Duke University School of Medicine, Duke University Medical Center, Box 3913, Durham, NC 27710, USA
| | - Amit Patel
- Division of Gastroenterology, Duke University School of Medicine, 10207 Cerny Street, Suite 200, Raleigh, NC 27617, USA; Division of Gastroenterology, Durham Veterans Affairs Medical Center.
| |
Collapse
|
3
|
Barnes EL, Esckilsen S, Ashburn J, Barto A, Bloomfeld R, Cairns A, Mehta K, Patel P, Dziwis J, Dunn MS, Rahbar R, Sadiq TS, Hanson JS, Herfarth HH. Extensive Colitis and Smoking Are Associated With Postoperative Complications Within 30 Days of Ileal Pouch-Anal Anastomosis. Inflamm Bowel Dis 2023:izad177. [PMID: 37607334 DOI: 10.1093/ibd/izad177] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Grants] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 04/28/2023] [Indexed: 08/24/2023]
Abstract
BACKGROUND Our understanding of outcomes after proctocolectomy with ileal pouch-anal anastomosis (IPAA) for ulcerative colitis (UC) is largely based on analyses of selected populations. We created a state-level registry to evaluate the epidemiology of IPAA surgery and pouch-related outcomes across the major healthcare systems performing these surgeries in our state. METHODS We created a retrospective cohort of all patients undergoing restorative proctocolectomy with IPAA for UC at 1 of 4 centers between January 1, 2018, and December 31, 2020. The primary outcomes of this study were the rate of complications and all-cause readmissions within the first 30 days of the final stage of IPAA surgery. RESULTS During the study period, 177 patients underwent IPAA surgery with 66 (37%) experiencing a complication within 30 days. After adjusting for the number of stages in IPAA surgery, patients with extensive UC (odds ratio, 3.61; 95% confidence interval, 1.39-9.33) and current or former smokers (odds ratio, 2.98; 95% confidence interval, 1.38-6.45) were more likely to experience a complication. Among all patients, 57 (32%) required readmission within 30 days. The most common reasons for readmission were ileus/small bowel obstruction (22%), peripouch abscess (19%), and dehydration (16%). CONCLUSION In this first state-level examination of the epidemiology of IPAA for UC, we demonstrated that the complication rate after IPAA for UC was 37%, with one-third of patients being readmitted within 30 days. Extensive disease at the time of colectomy appears to be an indicator of more severe disease and may portend a worse prognosis after IPAA.
Collapse
Affiliation(s)
- Edward L Barnes
- Division of Gastroenterology and Hepatology, University of North Carolina, Chapel Hill, NC, USA
- Center for Gastrointestinal Biology and Disease, University of North Carolina, Chapel Hill, NC, USA
| | - Scott Esckilsen
- Department of Medicine, University of North Carolina, Chapel Hill, NC, USA
| | - Jean Ashburn
- Division of Colon and Rectal Surgery, Atrium Health at Wake Forest Baptist, Winston-Salem, NC, USA
| | - Amy Barto
- Division of Gastroenterology and Hepatology, Duke University, Durham, NC, USA
| | - Richard Bloomfeld
- Section of Gastroenterology, Atrium Health at Wake Forest Baptist, Winston-Salem, NC, USA
| | - Ashley Cairns
- Division of Colon and Rectal Surgery, Atrium Health at Wake Forest Baptist, Winston-Salem, NC, USA
| | - Kurren Mehta
- Department of Medicine, Duke University, Durham, NC, USA
| | - Pooja Patel
- Department of Medicine, Duke University, Durham, NC, USA
| | - Jennifer Dziwis
- Section of Gastroenterology, Atrium Health at Wake Forest Baptist, Winston-Salem, NC, USA
- Department of Medicine, Duke University, Durham, NC, USA
| | - Michael S Dunn
- University of North Carolina School of Medicine, Chapel Hill, NC, USA
| | | | | | - John S Hanson
- Division of Gastroenterology and Hepatology, Atrium Health, Charlotte, NC, USA
| | - Hans H Herfarth
- Division of Gastroenterology and Hepatology, University of North Carolina, Chapel Hill, NC, USA
- Center for Gastrointestinal Biology and Disease, University of North Carolina, Chapel Hill, NC, USA
| |
Collapse
|
4
|
Mehta K, Panse C. Effect of Covid-19 pandemic: tourism and hospitality industry. CM 2022. [DOI: 10.18137/cardiometry.2022.22.406414] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/08/2022] Open
Abstract
The coronavirus, which causes COVID-19 disease, has unimaginably affected every industry. Among all industries, the tourism and hospitality industry is considered the worst-hit industry, contributing 9% of India’s total GDP; this paper presents an overview of the Indian tourism and hospitality industry before COVID-19. While sending out survey forms, we included general questions like gender, occupation, age, level of education, yearly income, what used to be their choice of location for a holiday before COVID-19, how much they yearly spent on holiday, how they plan their holiday trip, to understand the basic details and reliability of participants, also we did not ask the name of a participant to maintain the anonymity and privacy of a participant, which helped us to get an accurate data. How customers’ changed mindsets different priorities forced the tourism and hospitality industry to change the way of providing service also how the changed time has forced businesses to look for other opportunities to survive in the industry, Moreover here we have test different Sanitization and safety measurements using Friedman test to understand what are the factors that can affect the business of tourism and hospitality industry after the COVID-19 pandemic, as observed by Assaf & Scuderi.
Collapse
|
5
|
Moss K, Russell L, Mehta K, Faisal M, Armstrong D, Verdu E, Dowhaniuk J, Pinto-Sanchez MI. A194 THE ADDITION OF DEAMIDATED GLIADIN PEPTIDE TO TISSUE TRANSGLUTAMINASE ANTIBODIES DOES NOT INCREASE THE ODDS OF CELIAC DISEASE DIAGNOSIS IN AN IGA SUFFICIENT POPULATION. J Can Assoc Gastroenterol 2022. [PMCID: PMC8859345 DOI: 10.1093/jcag/gwab049.193] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
Abstract
Abstract
Background
Previous studies proposed that the combination of IgA anti-tissue transglutaminase 2 IgA (TTG) and IgG deamidated gliadin peptide IgG (DGP) antibodies increases celiac disease (CeD) detection rates. However, this remains controversial.
Aims
To evaluate the performance of adding DGP to TTG antibodies, for the diagnosis of celiac disease (CeD) in the immunoglobulin A (IgA)-sufficient population.
Methods
We included consecutive patients with suspected CeD who had both TTG and DGP serology performed simultaneously from 2017–2020 in Hamilton, Canada. Chart review was performed by 3 reviewers to extract data on biopsies, diagnosis of CeD and genetic HLA-DQ2/DQ8. CeD was defined as positive serology (either TTG and/or DGP) and villous atrophy in duodenal biopsies (≥Marsh-3a). A case was defined as an instance of TTG and DGP performed at a single timepoint. A single patient could have represented multiple cases if TTG and DGP were measured at multiple time points. Sensitivity, specificity, negative and positive predictive values were calculated, and ROC curves were generated. Diagnostic odds ratios (DOR) assessed the performance of each serological strategy compared to duodenal biopsies.
Results
There were 580 patients constituting 823 cases that met inclusion criteria, of whom 441 had CeD. IgA-deficient patients (n=100) were excluded. Of the 723 cases remaining, 337 (214 adult;123 pediatric) had serology performed at the time of CeD diagnosis. TTG increased the odds of CeD diagnosis compared with DGP, Diagnostic Odds Ratio (DOR)=53.22 (95% CI 22.63–119.80) vs DOR=21.28 (95% CI 10.67–42.46). The addition of DGP to TTG did not increase the odds of CeD diagnosis [DGP+TTG DOR=51.39 (95% CI 19.36–135.61) vs TTG alone DOR=53.22 (95% CI 22.63–119.80)]. There were 37 discordant cases where only one of either TTG or DGP was positive. HLA-DQ2/DQ8 were absent in 2/9 cases with isolated increased DGP. Among the discordant cases, TTG outperformed DGP (DOR TTG= 4.29; 95% CI 1.09–16.83 vs DOR DGP=0.23; 95% CI 0.06–0.92).
Conclusions
In the IgA-sufficient population, the addition of DGP to TTG testing does not increase the diagnostic accuracy of CeD serologic screening. This has implications in health-care costs as false positive results prompt further investigations. Given these findings, larger prospective studies should be completed prior to adding DGP antibodies to routine TTG serology.
Funding Agencies
None
Collapse
Affiliation(s)
- K Moss
- McMaster University Faculty of Health Sciences, Hamilton, ON, Canada
| | - L Russell
- McMaster University Faculty of Health Sciences, Hamilton, ON, Canada
| | - K Mehta
- McMaster University Faculty of Health Sciences, Hamilton, ON, Canada
| | - M Faisal
- McMaster University Faculty of Health Sciences, Hamilton, ON, Canada
| | - D Armstrong
- McMaster University Faculty of Health Sciences, Hamilton, ON, Canada
| | - E Verdu
- McMaster University Faculty of Health Sciences, Hamilton, ON, Canada
| | - J Dowhaniuk
- McMaster University Faculty of Health Sciences, Hamilton, ON, Canada
| | - M I Pinto-Sanchez
- McMaster University Faculty of Health Sciences, Hamilton, ON, Canada
| |
Collapse
|
6
|
Mehta K, Kaur B, Pandey KK, Dhar P, Kaler S. Resveratrol protects against inorganic arsenic-induced oxidative damage and cytoarchitectural alterations in female mouse hippocampus. Acta Histochem 2021; 123:151792. [PMID: 34634674 DOI: 10.1016/j.acthis.2021.151792] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/25/2021] [Revised: 09/13/2021] [Accepted: 09/16/2021] [Indexed: 01/04/2023]
Abstract
Prolonged inorganic arsenic (iAs) exposure is widely associated with brain damage particularly in the hippocampus via oxidative and apoptotic pathways. Resveratrol (RES) has gained considerable attention because of its benefits to human health. However, its neuroprotective potential against iAs-induced toxicity in CA1 region of hippocampus remains unexplored. Therefore, we investigated the neuroprotective efficacy of RES against arsenic trioxide (As2O3)-induced adverse effects on neuronal morphology, apoptotic markers and oxidative stress parameters in mouse CA1 region (hippocampus). Adult female Swiss albino mice of reproductive maturity were orally exposed to either As2O3 (2 and 4 mg/kg bw) alone or in combination with RES (40 mg/kg bw) for a period of 45 days. After animal sacrifice on day 46, the perfusion fixed brain samples were used for the observation of neuronal morphology and studying the morphometric features. While the freshly dissected hippocampi were processed for biochemical estimation of oxidative stress markers and western blotting of apoptosis-associated proteins. Chronic iAs exposure led to significant decrease in Stratum Pyramidale layer thickness along with reduction in cell density and area of Pyramidal neurons in contrast to the controls. Biochemical analysis showed reduced hippocampal GSH content but no change in total nitrite (NO) levels following iAs exposure. Western blotting showed apparent changes in the expression levels of Bax and Bcl-2 proteins following iAs exposure, however the change was statistically insignificant. Contrastingly, iAs +RES co-treatment exhibited substantial reversal in morphological and biochemical observations. Together, these findings provide preliminary evidence of neuroprotective role of RES on structural and biochemical alterations pertaining to mouse hippocampus following chronic iAs exposure.
Collapse
Affiliation(s)
- K Mehta
- Department of Anatomy, All India Institute of Medical Sciences (AIIMS), New Delhi 110029, India
| | - B Kaur
- Department of Anatomy, All India Institute of Medical Sciences (AIIMS), New Delhi 110029, India
| | - K K Pandey
- Department of Anatomy, All India Institute of Medical Sciences (AIIMS), New Delhi 110029, India
| | - P Dhar
- Department of Anatomy, All India Institute of Medical Sciences (AIIMS), New Delhi 110029, India
| | - S Kaler
- Department of Anatomy, All India Institute of Medical Sciences (AIIMS), New Delhi 110029, India.
| |
Collapse
|
7
|
Jacobs CD, Mehta K, Gao J, Wang X, Salama JK, Kelsey CR, Torok JA. Nomogram Predicting Overall Survival Benefit of Stereotactic Ablative Radiotherapy for Early-Stage Non-Small Cell Lung Cancer. Clin Lung Cancer 2021; 23:177-184. [PMID: 34301453 DOI: 10.1016/j.cllc.2021.06.008] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/02/2021] [Revised: 05/27/2021] [Accepted: 06/15/2021] [Indexed: 12/25/2022]
Abstract
OBJECTIVES To develop and validate a nomogram that predicts overall survival (OS) for patients with early-stage non-small cell lung cancer (NSCLC) treated with stereotactic ablative radiotherapy (SABR) vs. observation. MATERIALS AND METHODS Adults with biopsy-proven T1-T2N0 NCSLC treated with SABR (30-70 Gy in 1-10 fractions with biologically effective dose ≥100 Gy10) or observation between 2004 and 2015 in the National Cancer Database (NCDB) were identified. Propensity score was used to match SABR and observation cohorts on prognostic demographic and clinicopathologic factors identified by logistic regression. Using backward selection, a multivariable Cox proportional hazard was identified predicting 2- and 5-year OS via a nomogram. Model prediction accuracy was assessed by time-dependent receiver operating characteristic (ROC) curves and integrated area under the ROC curve (AUC) analysis. RESULTS A total of 22,073 adults met inclusion criteria and 4418 matched pairs (total n = 8836) were identified for nomogram development. The factors most strongly associated with improved OS on multivariable analysis included younger age (HR 0.82 by decade, P < .001), female sex (HR 0.81, P < .001), lower comorbidity index (HR 0.65 for 0 vs. ≥3, P < .001), smaller tumor size (HR 0.60 for ≤3 cm vs. 5.1-7 cm, P < .001), adenocarcinoma histology (P < .001), and receipt of SABR (P < .001). Interaction between SABR and histology was significantly associated with OS (P = .017). Relative to adenocarcinoma, patients with squamous cell carcinoma who were observed (HR 1.44, 95% CI 1.33-1.56) or treated with SABR (HR 1.24, 95% CI 1.14-1.35) had significantly worse OS. The nomogram demonstrated fair accuracy for predicting OS, with an integrated time-dependent AUC of 0.694 over the entire follow-up period. CONCLUSION This nomogram estimates OS at 2 and 5 years based on whether medically inoperable early-stage NSCLC patients receive SABR or elect for observation. Incorporation of other variables not captured within the NCDB may improve the model accuracy.
Collapse
Affiliation(s)
- Corbin D Jacobs
- Department of Radiation Oncology, Duke University Medical Center, Durham, NC
| | - Kurren Mehta
- Department of Internal Medicine, Duke University Hospital, Durham, NC
| | - Junheng Gao
- Department of Biostatistics and Bioinformatics, Duke University Medical Center, Durham, NC
| | - Xiaofei Wang
- Department of Biostatistics and Bioinformatics, Duke University Medical Center, Durham, NC
| | - Joseph K Salama
- Department of Radiation Oncology, Duke University Medical Center, Durham, NC
| | - Chris R Kelsey
- Department of Radiation Oncology, Duke University Medical Center, Durham, NC
| | - Jordan A Torok
- Department of Radiation Oncology, Duke University Medical Center, Durham, NC.
| |
Collapse
|
8
|
AHMAD S, Bhasin N, Sinha S, Sayed S, Bansode J, Swami R, Mehta K. POS-467 RENAL AND HEPATIC OUTCOMES AFTER REMDESIVIR THERAPY IN COVID-19 POSITIVE PATIENTS WITH RENAL DYSFUNCTION AT BASELINE OR AFTER STARTING THERAPY. Kidney Int Rep 2021. [PMCID: PMC8049664 DOI: 10.1016/j.ekir.2021.03.494] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/22/2022] Open
|
9
|
Abstract
As the demographic characteristics of the US population have changed over the past decade, the characteristics of different homeless populations have changed as well. This study tracked changes in demographic characteristics of homeless adult, veteran, and healthcare service user populations against general adult and veteran populations from 2007-2017. The results showed that changing demographics of homeless populations largely reflected broader trends in the general population, and attention is needed on the clinical needs of aging homeless populations. There may be some unique changes in the demography of some homeless populations, such as younger homeless veterans seeking healthcare services.
Collapse
Affiliation(s)
- J Tsai
- U.S. Department of Veterans Affairs, National Center on Homelessness Among Veterans, Tampa, FL, USA
- Department of Psychiatry, Yale University School of Medicine, VACT, 950 Campbell Ave., 151D, West Haven, New Haven, CT 06516, USA
| | - K Mehta
- U.S. Department of Veterans Affairs, National Center on Homelessness among Veterans, Tampa, FL, USA
| | - AE Mongtomery
- U.S. Department of Veterans Affairs, National Center on Homelessness among Veterans, Tampa, FL, USA
- Department of Health Behavior, School of Public Health, University of Alabama at Birmingham, Birmingham, AL, USA
| | - E Elbogen
- U.S. Department of Veterans Affairs, National Center on Homelessness among Veterans, Tampa, FL, USA
- Department of Psychiatry, Duke University School of Medicine, Durham, NC, USA
| | - D Hooshyar
- U.S. Department of Veterans Affairs, National Center on Homelessness among Veterans, Tampa, FL, USA
- Department of Psychiatry, University of Texas Southwestern Medical Center, Dallas, TX, USA
| |
Collapse
|
10
|
Posner S, Mehta K, Parish A, Niedzwiecki D, Gupta RT, Fisher DA, Leiman DA. Esophageal Function Tests are Not Associated with Barium Swallow Findings in Advanced Lung Disease. Dysphagia 2020; 35:864-870. [PMID: 32277290 DOI: 10.1007/s00455-020-10113-2] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/30/2019] [Accepted: 04/03/2020] [Indexed: 11/29/2022]
Abstract
Gastroesophageal reflux disease and esophageal dysmotility are common in patients with advanced lung disease (ALD) and are associated with worse outcomes. Assessing esophageal function in these patients is relevant for determining pulmonary transplant eligibility and prognosticating post-transplant outcomes. Barium Swallow (BaS) is a non-invasive testing modality often performed as a complement to formal esophageal function tests (EFTs), but its role and clinical utility in this context is unknown. Therefore, we aimed to determine the relationship between BaS and EFTs with high-resolution manometry (HRM) and 24-h ambulatory pH-metry in patients with ALD. We performed a retrospective study of 226 consecutive patients undergoing evaluation for lung transplantation at a single center. All patients underwent EFTs and BaS independent of clinical history or symptoms per institutional protocol. Appropriate statistical tests were performed to evaluate the relationship between EFTs and BaS. Mucosal, reflux and motility findings were categorized. Abnormal motility was reported in 133 (59%) patients by BaS and 99 (44%) by HRM, with a significant difference in the proportions of patients with abnormal studies (p < 0.01). There were 7 (26%) patients with abnormal barium tablet passage who had normal HRM. The sensitivity (35%) and specificity (77%) for detecting pathologic reflux with BaS was poor. Inducibility of reflux and barium column height were not associated with pH-metry results. No clinically significant luminal irregularities were identified. In conclusion, while BaS can non-invasively assess esophageal mucosa, its findings are not associated with EFTs in patients with ALD.
Collapse
Affiliation(s)
- Shai Posner
- Division of Gastroenterology, Duke University School of Medicine, 200 Morris Street, Durham, NC, 27705, USA
| | - Kurren Mehta
- Duke University School of Medicine, Duke University, Durham, NC, USA
| | - Alice Parish
- Department of Biostatistics and Bioinformatics, Duke University, Durham, NC, USA
| | - Donna Niedzwiecki
- Department of Biostatistics and Bioinformatics, Duke University, Durham, NC, USA
| | - Rajan T Gupta
- Department of Radiology, Duke University, Durham, NC, USA
| | - Deborah A Fisher
- Division of Gastroenterology, Duke University School of Medicine, 200 Morris Street, Durham, NC, 27705, USA.,Duke Clinical Research Institute, Durham, NC, USA
| | - David A Leiman
- Division of Gastroenterology, Duke University School of Medicine, 200 Morris Street, Durham, NC, 27705, USA. .,Duke Clinical Research Institute, Durham, NC, USA.
| |
Collapse
|
11
|
Olivere LA, Rhodin KE, Hong C, Oyekunle T, Howell E, Giri VK, Mehta K, Tong BC, Sosa JA, Fayanju OM. Educational Outcomes of a Pre-Clinical Medical Student Curriculum with Medicaid and Uninsured Surgical Oncology Patients. J Am Coll Surg 2019. [DOI: 10.1016/j.jamcollsurg.2019.08.527] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/25/2022]
|
12
|
Martín M, Loibl S, Hyslop T, De la Haba-Rodríguez J, Aktas B, Cirrincione CT, Mehta K, Barry WT, Morales S, Carey LA, Garcia-Saenz JA, Partridge A, Martinez-Jañez N, Hahn O, Winer E, Guerrero-Zotano A, Hudis C, Casas M, Rodriguez-Martin C, Furlanetto J, Carrasco E, Dickler MN. Evaluating the addition of bevacizumab to endocrine therapy as first-line treatment for hormone receptor-positive metastatic breast cancer: a pooled analysis from the LEA (GEICAM/2006-11_GBG51) and CALGB 40503 (Alliance) trials. Eur J Cancer 2019; 117:91-98. [PMID: 31276981 DOI: 10.1016/j.ejca.2019.06.002] [Citation(s) in RCA: 9] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/05/2019] [Revised: 05/20/2019] [Accepted: 06/02/2019] [Indexed: 10/26/2022]
Abstract
BACKGROUND Randomised trials comparing the efficacy of standard endocrine therapy (ET) versus experimental ET + bevacizumab (Bev) in 1st line hormone receptor-positive patients with metastatic breast cancer have thus far shown conflicting results. PATIENTS AND METHODS We pooled data from two similar phase III randomised trials of ET ± Bev (LEA and Cancer and Leukemia Group B 40503) to increase precision in estimating treatment effect. Primary end-point was progression-free survival (PFS). Secondary end-points were overall survival (OS), objective response rate (ORR), clinical benefit rate (CBR) and safety. Exploratory analyses were performed within subgroups defined by patients with recurrent disease, de novo disease, prior endocrine sensitivity or resistance and reported grades III-IV hypertension and proteinuria. RESULTS The pooled sample consisted of 749 patients randomised to ET or ET + Bev. Median PFS was 14.3 months for ET versus 19 months for ET + Bev (unadjusted hazard ratio [HR] 0.77; 95% confidence interval [CI] 0.66-0.91; p < 0.01). ORR and CBR with ET and ET + Bev were 40 versus 61% (p < 0.01) and 64 versus 77% (p < 0.01), respectively. There was no difference in OS (HR 0.96; 95% CI 0.77-1.18; p = 0.68). PFS was superior for ET + Bev for endocrine-sensitive patients (HR 0.68; 95% CI 0.53-0.89; p = 0.004). Grade III-IV hypertension (2.2 versus 20.1%), proteinuria (0 versus 9.3%), cardiovascular (0.5 versus 4.2%) and liver events (0 versus 2.9%) were significantly higher for ET + Bev (all p < 0.01). Hypertension and proteinuria were not predictors of efficacy (interaction test p = 0.33). CONCLUSION The addition of Bev to ET increased PFS overall and in endocrine-sensitive patients but not OS at the expense of significant additional toxicity. TRIALS REGISTRATION ClinicalTrial.Gov NCT00545077 and NCT00601900.
Collapse
Affiliation(s)
- M Martín
- Medical Oncology, Instituto de Investigación Sanitaria Gregorio Marañón, Universidad Complutense Madrid, Centro de Investigación Biomédica en Red de Oncología, CIBERONC-ISCIII, GEICAM Spanish Breast Cancer Group, Spain.
| | - S Loibl
- GBG (German Breast Group), Neu-Isenburg, Germany
| | - T Hyslop
- Alliance Statistics and Data Center, Duke University, Durham, NC, USA
| | - J De la Haba-Rodríguez
- Oncology Department and Research Unit, Instituto Maimónides de Investigación Biomédica de Córdoba, Hospital Reina Sofía, Universidad de Córdoba Spain. Centro de Investigación Biomédica en Red de Oncología, CIBERONC-ISCIII, GEICAM Spanish Breast Cancer Group, Spain
| | - B Aktas
- University Women's Hospital Leipzig, Leipzig, Germany
| | - C T Cirrincione
- Alliance Statistics and Data Center, Duke University, Durham, NC, USA
| | - K Mehta
- GBG (German Breast Group), Neu-Isenburg, Germany
| | - W T Barry
- Alliance Statistics and Data Center, Dana-Farber/Partners Cancer Care, Boston, MA, USA
| | - S Morales
- Medical Oncology, Hospital Arnau de Vilanova de Lérida, GEICAM Spanish Breast Cancer Group, Spain
| | - L A Carey
- University of North Carolina, Chapel Hill, NC, USA
| | - J A Garcia-Saenz
- Medical Oncology, Instituto de Investigación Sanitaria del Hospital Clinico San Carlos (IdISSC) Madrid, Centro de Investigación Biomédica en Red de Oncología, CIBERONC-ISCIII, GEICAM Spanish Breast Cancer Group, Spain
| | - A Partridge
- Dana-Farber/Partners CancerCare, Boston, MA, USA
| | - N Martinez-Jañez
- Medical Oncology. Universitary Hospital Ramon y Cajal. GEICAM, Spanish Breast Cancer Group; Madrid, Spain
| | - O Hahn
- Alliance Protocol Operations Office, University of Chicago, Chicago, IL, USA
| | - E Winer
- Dana-Farber/Partners CancerCare, Boston, MA, USA
| | - A Guerrero-Zotano
- Medical Oncology. Valencian Institute of Oncology. GEICAM Spanish Breast Cancer Group, Valencia, Spain
| | - C Hudis
- American Society of Clinical Oncology (ASCO), Alexandria, VA, USA
| | - M Casas
- GEICAM Spanish Breast Cancer Group, Madrid, Spain
| | | | - J Furlanetto
- GBG (German Breast Group), Neu-Isenburg, Germany
| | - E Carrasco
- GEICAM Spanish Breast Cancer Group, Madrid, Spain
| | | | | | | | | |
Collapse
|
13
|
Jacobs CD, Barak I, Mehta K, Agassi AM, Jung SH, Suneja G, Brizel DM, Mowery YM. Utilization of Brachytherapy for Early Stage Oral Cavity Cancers in the United States. Brachytherapy 2019. [DOI: 10.1016/j.brachy.2019.04.063] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/26/2022]
|
14
|
Flühmann C, Nguyen TL, Marinelli M, Negnevitsky V, Mehta K, Home JP. Encoding a qubit in a trapped-ion mechanical oscillator. Nature 2019; 566:513-517. [DOI: 10.1038/s41586-019-0960-6] [Citation(s) in RCA: 152] [Impact Index Per Article: 30.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/11/2018] [Accepted: 01/04/2019] [Indexed: 11/09/2022]
|
15
|
Huober J, Schneeweiss A, Blohmer JU, Denkert C, Tesch H, Hanusch CA, Salat C, Rhiem K, Rezai M, Solbach C, Fasching PA, Jackisch C, Mehta K, Nekljudova V, Seither F, von Minckwitz G, Loibl S, Untch M. Abstract P2-08-01: Factors predicting relapse in early breast cancer patients with a pathological complete response after neoadjuvant therapy – Results of a pooled analysis based on the GBG meta-database. Cancer Res 2019. [DOI: 10.1158/1538-7445.sabcs18-p2-08-01] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Background
Even though patients with a pCR following neoadjuvant chemotherapy have an excellent prognosis still some of these patients will eventually relapse. A better identification of pts with an increased risk of relapse despite a pCR would be helpful to select these patients for additional post-neoadjuvant treatment strategies. Thus, the rationale of this retrospective analysis was to identify factors predicting relapse despite a pCR.
Methods
This pooled retrospective analysis based on the GBG meta-database includes the neoadjuvant trials GeparTrio, GeparQuattro, GeparQuinto, GeparSixto and GeparSepto. In these trials 2188 (27%) of 7933 pts had a pCR according to ypT0/ypTis ypN0 Definition and were included. The primary endpoint was disease-free survival (DFS), secondary endpoints were distant DFS (DDFS) and overall survival (OS). A multivariate Cox proportional hazards model was used to report hazard ratios with 95% confidence interval (CI). The two-sided significance level was set to α=0.05. Endpoints were analysed for all pts and in subgroups defined by intrinsic subtypes. The potential risk factors intrinsic subtype (HER2 negative/hormone receptor (HR) positive, triple negative, HER2 positive/HR positive, HER2 positive/HR negative), histological tumor type (lobular vs other), grade (G1/G2 vs G3), KI67 (≤20% vs higher), initial cT and cN stadium (cT1 vs cT2 vs cT3/4; cN0 vs cN+), age (≤40 vs 41-59 vs ≥60), BMI (< 25 vs 25-29 vs ≥ 30), planned number of cycles of chemotherapy (≤6 vs > 6), menopausal status (pre- vs postmenopausal) and clinical response after 2-4 cycles (SD vs PR vs CR vs PD) were included as covariates in multivariate Cox regression models as well as study identification.
Results
From 2188 evaluable patients DFS, DDFS and OS events were observed in 290/197/130 pts respectively; the median follow-up over all studies was 59 months. In multivariate analysis including study and all potential risk factors DFS was significantly different with regard to the initial cN status (cN+ vs cN0, hazard ratio (HR) 1.70; 95% CI [1.2, 2.4], p=0.002). Of borderline significance was histological type (non-lobular vs lobular, HR 0.52 95% CI [0.3, 1.1]; p=0.076) and initial tumor stage (cT3/4 vs cT1, HR 1.61 95% CI [1.0, 2.7]; p=0.064). In terms of DDFS significant differences were seen for the initial cN status (cN+ vs cN0, HR 2.34; 95% CI [1.5, 3.6], p<0.001) and initial tumor stage (cT3/4 vs cT1, HR 1.83 95% CI [1.0, 3.3]; p=0.044); histological type was again close to significance (non-lobular vs lobular, HR 0.46 95% CI [0.2, 1.1]; p=0.067). Multivariate analysis showed significantly worse OS with initial cT3/4 tumors (cT3/4 vs cT1, HR 2.48 95%CI [1.1, 5.7]; p=0.030), and the lobular type (non-lobular vs lobular, HR 0.35 95% CI [0.1, 0.9]; p=0.026) and a trend for worse OS in pts with cN+ (cN+ vs cN0, HR 1.67 95% CI [1.0, 2.9]; p=0.067).
Conclusions
Initial tumor load before start of neoadjuvant chemotherapy (tumor stage and nodal status) and lobular subtype were predictors of long term outcome after a pCR following neoadjuvant chemotherapy. Intrinsic subtype, KI67, grade and planned number of cycles were not predictive for a relapse.
Citation Format: Huober J, Schneeweiss A, Blohmer J-U, Denkert C, Tesch H, Hanusch CA, Salat C, Rhiem K, Rezai M, Solbach C, Fasching PA, Jackisch C, Mehta K, Nekljudova V, Seither F, von Minckwitz G, Loibl S, Untch M. Factors predicting relapse in early breast cancer patients with a pathological complete response after neoadjuvant therapy – Results of a pooled analysis based on the GBG meta-database [abstract]. In: Proceedings of the 2018 San Antonio Breast Cancer Symposium; 2018 Dec 4-8; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2019;79(4 Suppl):Abstract nr P2-08-01.
Collapse
Affiliation(s)
- J Huober
- Universitätsfrauenklink, Brustzentrum, Ulm, Germany; Nationales Centrum für Tumorerkrankungen, Heidelberg, Germany; Brustzentrum, Charité-Universitätsmedizin, Berlin, Germany; Institut für Pathologie, Charité-Universitätsmedizin, Berlin, Germany; Centrum für Hämatologie und Onkologie Bethanien, Frankfurt, Germany; Klinikum zum Roten Kreuz, München, Germany; Zentrum für Hämatologie und Onkologie, München, Germany; Zentrum Familiärer Brust- und Eierstockkrebs, Universitätsklinikum, Köln, Germany; Medical Center, Luisenkrankenhaus, Düsseldorf, Germany; Universitätsklinikum, Frankfurt, Germany; Brustzentrum, Universitätsklinikum, Erlangen, Germany; Sana Klinikum, Offenbach, Germany; German Breast Group, Neu-Isenburg, Germany; HELIOS Klinikum, Berlin-Buch, Germany
| | - A Schneeweiss
- Universitätsfrauenklink, Brustzentrum, Ulm, Germany; Nationales Centrum für Tumorerkrankungen, Heidelberg, Germany; Brustzentrum, Charité-Universitätsmedizin, Berlin, Germany; Institut für Pathologie, Charité-Universitätsmedizin, Berlin, Germany; Centrum für Hämatologie und Onkologie Bethanien, Frankfurt, Germany; Klinikum zum Roten Kreuz, München, Germany; Zentrum für Hämatologie und Onkologie, München, Germany; Zentrum Familiärer Brust- und Eierstockkrebs, Universitätsklinikum, Köln, Germany; Medical Center, Luisenkrankenhaus, Düsseldorf, Germany; Universitätsklinikum, Frankfurt, Germany; Brustzentrum, Universitätsklinikum, Erlangen, Germany; Sana Klinikum, Offenbach, Germany; German Breast Group, Neu-Isenburg, Germany; HELIOS Klinikum, Berlin-Buch, Germany
| | - J-U Blohmer
- Universitätsfrauenklink, Brustzentrum, Ulm, Germany; Nationales Centrum für Tumorerkrankungen, Heidelberg, Germany; Brustzentrum, Charité-Universitätsmedizin, Berlin, Germany; Institut für Pathologie, Charité-Universitätsmedizin, Berlin, Germany; Centrum für Hämatologie und Onkologie Bethanien, Frankfurt, Germany; Klinikum zum Roten Kreuz, München, Germany; Zentrum für Hämatologie und Onkologie, München, Germany; Zentrum Familiärer Brust- und Eierstockkrebs, Universitätsklinikum, Köln, Germany; Medical Center, Luisenkrankenhaus, Düsseldorf, Germany; Universitätsklinikum, Frankfurt, Germany; Brustzentrum, Universitätsklinikum, Erlangen, Germany; Sana Klinikum, Offenbach, Germany; German Breast Group, Neu-Isenburg, Germany; HELIOS Klinikum, Berlin-Buch, Germany
| | - C Denkert
- Universitätsfrauenklink, Brustzentrum, Ulm, Germany; Nationales Centrum für Tumorerkrankungen, Heidelberg, Germany; Brustzentrum, Charité-Universitätsmedizin, Berlin, Germany; Institut für Pathologie, Charité-Universitätsmedizin, Berlin, Germany; Centrum für Hämatologie und Onkologie Bethanien, Frankfurt, Germany; Klinikum zum Roten Kreuz, München, Germany; Zentrum für Hämatologie und Onkologie, München, Germany; Zentrum Familiärer Brust- und Eierstockkrebs, Universitätsklinikum, Köln, Germany; Medical Center, Luisenkrankenhaus, Düsseldorf, Germany; Universitätsklinikum, Frankfurt, Germany; Brustzentrum, Universitätsklinikum, Erlangen, Germany; Sana Klinikum, Offenbach, Germany; German Breast Group, Neu-Isenburg, Germany; HELIOS Klinikum, Berlin-Buch, Germany
| | - H Tesch
- Universitätsfrauenklink, Brustzentrum, Ulm, Germany; Nationales Centrum für Tumorerkrankungen, Heidelberg, Germany; Brustzentrum, Charité-Universitätsmedizin, Berlin, Germany; Institut für Pathologie, Charité-Universitätsmedizin, Berlin, Germany; Centrum für Hämatologie und Onkologie Bethanien, Frankfurt, Germany; Klinikum zum Roten Kreuz, München, Germany; Zentrum für Hämatologie und Onkologie, München, Germany; Zentrum Familiärer Brust- und Eierstockkrebs, Universitätsklinikum, Köln, Germany; Medical Center, Luisenkrankenhaus, Düsseldorf, Germany; Universitätsklinikum, Frankfurt, Germany; Brustzentrum, Universitätsklinikum, Erlangen, Germany; Sana Klinikum, Offenbach, Germany; German Breast Group, Neu-Isenburg, Germany; HELIOS Klinikum, Berlin-Buch, Germany
| | - CA Hanusch
- Universitätsfrauenklink, Brustzentrum, Ulm, Germany; Nationales Centrum für Tumorerkrankungen, Heidelberg, Germany; Brustzentrum, Charité-Universitätsmedizin, Berlin, Germany; Institut für Pathologie, Charité-Universitätsmedizin, Berlin, Germany; Centrum für Hämatologie und Onkologie Bethanien, Frankfurt, Germany; Klinikum zum Roten Kreuz, München, Germany; Zentrum für Hämatologie und Onkologie, München, Germany; Zentrum Familiärer Brust- und Eierstockkrebs, Universitätsklinikum, Köln, Germany; Medical Center, Luisenkrankenhaus, Düsseldorf, Germany; Universitätsklinikum, Frankfurt, Germany; Brustzentrum, Universitätsklinikum, Erlangen, Germany; Sana Klinikum, Offenbach, Germany; German Breast Group, Neu-Isenburg, Germany; HELIOS Klinikum, Berlin-Buch, Germany
| | - C Salat
- Universitätsfrauenklink, Brustzentrum, Ulm, Germany; Nationales Centrum für Tumorerkrankungen, Heidelberg, Germany; Brustzentrum, Charité-Universitätsmedizin, Berlin, Germany; Institut für Pathologie, Charité-Universitätsmedizin, Berlin, Germany; Centrum für Hämatologie und Onkologie Bethanien, Frankfurt, Germany; Klinikum zum Roten Kreuz, München, Germany; Zentrum für Hämatologie und Onkologie, München, Germany; Zentrum Familiärer Brust- und Eierstockkrebs, Universitätsklinikum, Köln, Germany; Medical Center, Luisenkrankenhaus, Düsseldorf, Germany; Universitätsklinikum, Frankfurt, Germany; Brustzentrum, Universitätsklinikum, Erlangen, Germany; Sana Klinikum, Offenbach, Germany; German Breast Group, Neu-Isenburg, Germany; HELIOS Klinikum, Berlin-Buch, Germany
| | - K Rhiem
- Universitätsfrauenklink, Brustzentrum, Ulm, Germany; Nationales Centrum für Tumorerkrankungen, Heidelberg, Germany; Brustzentrum, Charité-Universitätsmedizin, Berlin, Germany; Institut für Pathologie, Charité-Universitätsmedizin, Berlin, Germany; Centrum für Hämatologie und Onkologie Bethanien, Frankfurt, Germany; Klinikum zum Roten Kreuz, München, Germany; Zentrum für Hämatologie und Onkologie, München, Germany; Zentrum Familiärer Brust- und Eierstockkrebs, Universitätsklinikum, Köln, Germany; Medical Center, Luisenkrankenhaus, Düsseldorf, Germany; Universitätsklinikum, Frankfurt, Germany; Brustzentrum, Universitätsklinikum, Erlangen, Germany; Sana Klinikum, Offenbach, Germany; German Breast Group, Neu-Isenburg, Germany; HELIOS Klinikum, Berlin-Buch, Germany
| | - M Rezai
- Universitätsfrauenklink, Brustzentrum, Ulm, Germany; Nationales Centrum für Tumorerkrankungen, Heidelberg, Germany; Brustzentrum, Charité-Universitätsmedizin, Berlin, Germany; Institut für Pathologie, Charité-Universitätsmedizin, Berlin, Germany; Centrum für Hämatologie und Onkologie Bethanien, Frankfurt, Germany; Klinikum zum Roten Kreuz, München, Germany; Zentrum für Hämatologie und Onkologie, München, Germany; Zentrum Familiärer Brust- und Eierstockkrebs, Universitätsklinikum, Köln, Germany; Medical Center, Luisenkrankenhaus, Düsseldorf, Germany; Universitätsklinikum, Frankfurt, Germany; Brustzentrum, Universitätsklinikum, Erlangen, Germany; Sana Klinikum, Offenbach, Germany; German Breast Group, Neu-Isenburg, Germany; HELIOS Klinikum, Berlin-Buch, Germany
| | - C Solbach
- Universitätsfrauenklink, Brustzentrum, Ulm, Germany; Nationales Centrum für Tumorerkrankungen, Heidelberg, Germany; Brustzentrum, Charité-Universitätsmedizin, Berlin, Germany; Institut für Pathologie, Charité-Universitätsmedizin, Berlin, Germany; Centrum für Hämatologie und Onkologie Bethanien, Frankfurt, Germany; Klinikum zum Roten Kreuz, München, Germany; Zentrum für Hämatologie und Onkologie, München, Germany; Zentrum Familiärer Brust- und Eierstockkrebs, Universitätsklinikum, Köln, Germany; Medical Center, Luisenkrankenhaus, Düsseldorf, Germany; Universitätsklinikum, Frankfurt, Germany; Brustzentrum, Universitätsklinikum, Erlangen, Germany; Sana Klinikum, Offenbach, Germany; German Breast Group, Neu-Isenburg, Germany; HELIOS Klinikum, Berlin-Buch, Germany
| | - PA Fasching
- Universitätsfrauenklink, Brustzentrum, Ulm, Germany; Nationales Centrum für Tumorerkrankungen, Heidelberg, Germany; Brustzentrum, Charité-Universitätsmedizin, Berlin, Germany; Institut für Pathologie, Charité-Universitätsmedizin, Berlin, Germany; Centrum für Hämatologie und Onkologie Bethanien, Frankfurt, Germany; Klinikum zum Roten Kreuz, München, Germany; Zentrum für Hämatologie und Onkologie, München, Germany; Zentrum Familiärer Brust- und Eierstockkrebs, Universitätsklinikum, Köln, Germany; Medical Center, Luisenkrankenhaus, Düsseldorf, Germany; Universitätsklinikum, Frankfurt, Germany; Brustzentrum, Universitätsklinikum, Erlangen, Germany; Sana Klinikum, Offenbach, Germany; German Breast Group, Neu-Isenburg, Germany; HELIOS Klinikum, Berlin-Buch, Germany
| | - C Jackisch
- Universitätsfrauenklink, Brustzentrum, Ulm, Germany; Nationales Centrum für Tumorerkrankungen, Heidelberg, Germany; Brustzentrum, Charité-Universitätsmedizin, Berlin, Germany; Institut für Pathologie, Charité-Universitätsmedizin, Berlin, Germany; Centrum für Hämatologie und Onkologie Bethanien, Frankfurt, Germany; Klinikum zum Roten Kreuz, München, Germany; Zentrum für Hämatologie und Onkologie, München, Germany; Zentrum Familiärer Brust- und Eierstockkrebs, Universitätsklinikum, Köln, Germany; Medical Center, Luisenkrankenhaus, Düsseldorf, Germany; Universitätsklinikum, Frankfurt, Germany; Brustzentrum, Universitätsklinikum, Erlangen, Germany; Sana Klinikum, Offenbach, Germany; German Breast Group, Neu-Isenburg, Germany; HELIOS Klinikum, Berlin-Buch, Germany
| | - K Mehta
- Universitätsfrauenklink, Brustzentrum, Ulm, Germany; Nationales Centrum für Tumorerkrankungen, Heidelberg, Germany; Brustzentrum, Charité-Universitätsmedizin, Berlin, Germany; Institut für Pathologie, Charité-Universitätsmedizin, Berlin, Germany; Centrum für Hämatologie und Onkologie Bethanien, Frankfurt, Germany; Klinikum zum Roten Kreuz, München, Germany; Zentrum für Hämatologie und Onkologie, München, Germany; Zentrum Familiärer Brust- und Eierstockkrebs, Universitätsklinikum, Köln, Germany; Medical Center, Luisenkrankenhaus, Düsseldorf, Germany; Universitätsklinikum, Frankfurt, Germany; Brustzentrum, Universitätsklinikum, Erlangen, Germany; Sana Klinikum, Offenbach, Germany; German Breast Group, Neu-Isenburg, Germany; HELIOS Klinikum, Berlin-Buch, Germany
| | - V Nekljudova
- Universitätsfrauenklink, Brustzentrum, Ulm, Germany; Nationales Centrum für Tumorerkrankungen, Heidelberg, Germany; Brustzentrum, Charité-Universitätsmedizin, Berlin, Germany; Institut für Pathologie, Charité-Universitätsmedizin, Berlin, Germany; Centrum für Hämatologie und Onkologie Bethanien, Frankfurt, Germany; Klinikum zum Roten Kreuz, München, Germany; Zentrum für Hämatologie und Onkologie, München, Germany; Zentrum Familiärer Brust- und Eierstockkrebs, Universitätsklinikum, Köln, Germany; Medical Center, Luisenkrankenhaus, Düsseldorf, Germany; Universitätsklinikum, Frankfurt, Germany; Brustzentrum, Universitätsklinikum, Erlangen, Germany; Sana Klinikum, Offenbach, Germany; German Breast Group, Neu-Isenburg, Germany; HELIOS Klinikum, Berlin-Buch, Germany
| | - F Seither
- Universitätsfrauenklink, Brustzentrum, Ulm, Germany; Nationales Centrum für Tumorerkrankungen, Heidelberg, Germany; Brustzentrum, Charité-Universitätsmedizin, Berlin, Germany; Institut für Pathologie, Charité-Universitätsmedizin, Berlin, Germany; Centrum für Hämatologie und Onkologie Bethanien, Frankfurt, Germany; Klinikum zum Roten Kreuz, München, Germany; Zentrum für Hämatologie und Onkologie, München, Germany; Zentrum Familiärer Brust- und Eierstockkrebs, Universitätsklinikum, Köln, Germany; Medical Center, Luisenkrankenhaus, Düsseldorf, Germany; Universitätsklinikum, Frankfurt, Germany; Brustzentrum, Universitätsklinikum, Erlangen, Germany; Sana Klinikum, Offenbach, Germany; German Breast Group, Neu-Isenburg, Germany; HELIOS Klinikum, Berlin-Buch, Germany
| | - G von Minckwitz
- Universitätsfrauenklink, Brustzentrum, Ulm, Germany; Nationales Centrum für Tumorerkrankungen, Heidelberg, Germany; Brustzentrum, Charité-Universitätsmedizin, Berlin, Germany; Institut für Pathologie, Charité-Universitätsmedizin, Berlin, Germany; Centrum für Hämatologie und Onkologie Bethanien, Frankfurt, Germany; Klinikum zum Roten Kreuz, München, Germany; Zentrum für Hämatologie und Onkologie, München, Germany; Zentrum Familiärer Brust- und Eierstockkrebs, Universitätsklinikum, Köln, Germany; Medical Center, Luisenkrankenhaus, Düsseldorf, Germany; Universitätsklinikum, Frankfurt, Germany; Brustzentrum, Universitätsklinikum, Erlangen, Germany; Sana Klinikum, Offenbach, Germany; German Breast Group, Neu-Isenburg, Germany; HELIOS Klinikum, Berlin-Buch, Germany
| | - S Loibl
- Universitätsfrauenklink, Brustzentrum, Ulm, Germany; Nationales Centrum für Tumorerkrankungen, Heidelberg, Germany; Brustzentrum, Charité-Universitätsmedizin, Berlin, Germany; Institut für Pathologie, Charité-Universitätsmedizin, Berlin, Germany; Centrum für Hämatologie und Onkologie Bethanien, Frankfurt, Germany; Klinikum zum Roten Kreuz, München, Germany; Zentrum für Hämatologie und Onkologie, München, Germany; Zentrum Familiärer Brust- und Eierstockkrebs, Universitätsklinikum, Köln, Germany; Medical Center, Luisenkrankenhaus, Düsseldorf, Germany; Universitätsklinikum, Frankfurt, Germany; Brustzentrum, Universitätsklinikum, Erlangen, Germany; Sana Klinikum, Offenbach, Germany; German Breast Group, Neu-Isenburg, Germany; HELIOS Klinikum, Berlin-Buch, Germany
| | - M Untch
- Universitätsfrauenklink, Brustzentrum, Ulm, Germany; Nationales Centrum für Tumorerkrankungen, Heidelberg, Germany; Brustzentrum, Charité-Universitätsmedizin, Berlin, Germany; Institut für Pathologie, Charité-Universitätsmedizin, Berlin, Germany; Centrum für Hämatologie und Onkologie Bethanien, Frankfurt, Germany; Klinikum zum Roten Kreuz, München, Germany; Zentrum für Hämatologie und Onkologie, München, Germany; Zentrum Familiärer Brust- und Eierstockkrebs, Universitätsklinikum, Köln, Germany; Medical Center, Luisenkrankenhaus, Düsseldorf, Germany; Universitätsklinikum, Frankfurt, Germany; Brustzentrum, Universitätsklinikum, Erlangen, Germany; Sana Klinikum, Offenbach, Germany; German Breast Group, Neu-Isenburg, Germany; HELIOS Klinikum, Berlin-Buch, Germany
| |
Collapse
|
16
|
Goneau LW, Mehta K, Wong J, L'Huillier AG, Gubbay JB. Zoonotic Influenza and Human Health-Part 1: Virology and Epidemiology of Zoonotic Influenzas. Curr Infect Dis Rep 2018; 20:37. [PMID: 30069735 DOI: 10.1007/s11908-018-0642-9] [Citation(s) in RCA: 8] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
Abstract
PURPOSE OF REVIEW Zoonotic influenza viruses are those that cross the animal-human barrier and can cause disease in humans, manifesting from minor respiratory illnesses to multiorgan dysfunction. They have also been implicated in the causation of deadly pandemics in recent history. The increasing incidence of infections caused by these viruses worldwide has necessitated focused attention to improve both diagnostic as well as treatment modalities. In this first part of a two-part review, we describe the structure of zoonotic influenza viruses, the relationship between mutation and pandemic capacity, pathogenesis of infection, and also discuss history and epidemiology. RECENT FINDINGS We are currently witnessing the fifth and the largest wave of the avian influenza A(H7N9) epidemic. Also in circulation are a number of other zoonotic influenza viruses, including avian influenza A(H5N1) and A(H5N6); avian influenza A(H7N2); and swine influenza A(H1N1)v, A(H1N2)v, and A(H3N2)v viruses. Most recently, the first human case of avian influenza A(H7N4) infection has been documented. By understanding the virology and epidemiology of emerging zoonotic influenzas, we are better prepared to face a new pandemic. However, continued effort is warranted to build on this knowledge in order to efficiently combat the constant threat posed by the zoonotic influenza viruses.
Collapse
Affiliation(s)
- L W Goneau
- Public Health Ontario Laboratory, 661 University Avenue, Suite 1701, Toronto, ON, M5G 1M1, Canada.,University of Toronto, 27 King's College Circle, Toronto, ON, M5S 1A1, Canada
| | - K Mehta
- Division of Infectious Diseases, Department of Paediatrics, The Hospital for Sick Children, Toronto, ON, Canada
| | - J Wong
- Division of Infectious Diseases, Department of Paediatrics, The Hospital for Sick Children, Toronto, ON, Canada.,Department of Paediatrics, University of Toronto, Toronto, ON, Canada.,Department of Paediatrics, North York General Hospital, Toronto, ON, Canada
| | - A G L'Huillier
- Division of Infectious Diseases, Department of Paediatrics, The Hospital for Sick Children, Toronto, ON, Canada
| | - J B Gubbay
- Public Health Ontario Laboratory, 661 University Avenue, Suite 1701, Toronto, ON, M5G 1M1, Canada. .,University of Toronto, 27 King's College Circle, Toronto, ON, M5S 1A1, Canada. .,Division of Infectious Diseases, Department of Paediatrics, The Hospital for Sick Children, Toronto, ON, Canada.
| |
Collapse
|
17
|
Mehta T, Desai N, Mehta K, Parikh R, Male S, Hussain M, Ollenschleger M, Spiegel G, Grande A, Ezzeddine M, Jagadeesan B, Tummala R, McCullough L. Outcomes of early carotid stenting and angioplasty in large-vessel anterior circulation strokes treated with mechanical thrombectomy and intravenous thrombolytics. Interv Neuroradiol 2018; 24:392-397. [PMID: 29697301 DOI: 10.1177/1591019918768574] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022] Open
Abstract
Introduction Proximal cervical internal carotid artery stenosis greater than 50% merits revascularization to mitigate the risk of stroke recurrence among large-vessel anterior circulation strokes undergoing mechanical thrombectomy. Carotid artery stenting necessitates the use of antiplatelets, and there is a theoretical increased risk of hemorrhagic transformation given that such patients may already have received intravenous thrombolytics and have a significant infarct burden. We investigate the outcomes of large-vessel anterior circulation stroke patients treated with intravenous thrombolytics receiving same-day carotid stenting or selective angioplasty compared to no carotid intervention. Materials and methods The study cohort was obtained from the National (Nationwide) Inpatient Sample database between 2006 and 2014, using International Statistical Classification of Diseases, ninth revision discharge diagnosis and procedure codes. A total of 11,825 patients with large-vessel anterior circulation stroke treated with intravenous thrombolytic and mechanical thrombectomy on the same day were identified. The study population was subdivided into three subgroups: no carotid intervention, same-day carotid angioplasty without carotid stenting, and same-day carotid stenting. Outcomes were assessed with respect to mortality, significant disability at discharge, hemorrhagic transformation, and requirement of percutaneous endoscopic gastronomy tube placement, prolonged mechanical ventilation, or craniotomy. Results This study found no statistically significant difference in patient outcomes in those treated with concurrent carotid stenting compared to no carotid intervention in terms of morbidity or mortality. Conclusions If indicated, it is reasonable to consider concurrent carotid stenting and/or angioplasty for large-vessel anterior circulation stroke patients treated with mechanical thrombectomy who also receive intravenous thrombolytics.
Collapse
Affiliation(s)
- T Mehta
- 1 Department of Neurology, University of Minnesota, Minneapolis, MN, USA
| | - N Desai
- 2 Department of Neurology, Hartford Hospital, Hartford, CT, USA
| | - K Mehta
- 3 Department of Hematology-Oncology, University of Pittsburgh Medical Center, Pittsburgh, PA, USA
| | - R Parikh
- 4 Department of Public Health, University of Minnesota, Minneapolis, MN, USA
| | - S Male
- 1 Department of Neurology, University of Minnesota, Minneapolis, MN, USA
| | - M Hussain
- 5 Department of Interventional Neuroradiology, Hartford Hospital, Hartford, CT, USA
| | - M Ollenschleger
- 5 Department of Interventional Neuroradiology, Hartford Hospital, Hartford, CT, USA
| | - G Spiegel
- 6 Department of Neuroradiology, University of Texas Health Sciences Center, Houston, TX, USA
| | - A Grande
- 7 Department of Neurosurgery, University of Minnesota, Minneapolis, MN, USA
| | - M Ezzeddine
- 1 Department of Neurology, University of Minnesota, Minneapolis, MN, USA
| | - B Jagadeesan
- 8 Department of Radiology, University of Minnesota, Minneapolis, MN, USA
| | - R Tummala
- 7 Department of Neurosurgery, University of Minnesota, Minneapolis, MN, USA
| | - L McCullough
- 9 Department of Neurology, University of Texas Health Sciences Center, Houston, TX, USA
| |
Collapse
|
18
|
Mehta K, Pajai A, Bhurke S, Shirkande A, Bhadade R, D'Souza R. Acute Kidney Injury of Infectious Etiology in Monsoon Season: A Prospective Study Using Acute Kidney Injury Network Criteria. Indian J Nephrol 2018; 28:143-152. [PMID: 29861565 PMCID: PMC5952453 DOI: 10.4103/ijn.ijn_355_16] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/16/2022] Open
Abstract
The epidemiological pattern of acute kidney injury (AKI) in tropical countries during monsoon reflects infectious disease as the most important cause. AKI is a confounding factor and may be overlooked by primary health-care providers and underreported in health statistics. The present study prospectively helps estimate the burden of disease and analyze etiology, clinical profile, and outcome in a tertiary care hospital of a metropolitan city in a tropical country. The study period included monsoon season of 2012 and 2013, a total of 8 months. AKI staging was done as per the AKI Network (AKIN) criteria. Patients were treated for primary disease. Renal replacement therapy (RRT) was given as required. Patients were followed up during hospitalization till recovery/death. Out of a total of 9930 admissions during this period, 1740 (17.52%) were for infections and 230 (2.31%) had AKI secondary to infectious diseases during monsoon. The incidence of AKI (230/1740) in infectious diseases during monsoon was 13.21%. The study population (n = 230) comprised 79.5% of males and the mean age was 40.95 ± 16.55 years. Severe AKI: AKIN Stage III was seen in 48.26% of patients and AKIN Stage I in 41.74%. The most common etiology of AKI was malaria (28.3%) followed by acute gastroenteritis (23%), dengue (16.5%), leptospirosis (13%), undifferentiated fever (10.4%), more than one etiology (5.4%), and enteric fever (3.5%). RRT was required in 44.78% of patients. Requirement for RRT was maximum in patients with more than one etiology followed by leptospirosis, malaria, dengue, and least in typhoid. The overall mortality was 12.17%. In multivariate analysis, vasopressor support and assisted ventilation were risk factors for mortality.
Collapse
Affiliation(s)
- K. Mehta
- Department of Nephrology, Topiwala National Medical College and B. Y. L. Nair Charitable Hospital, Mumbai, Maharashtra, India
| | - A. Pajai
- Department of Nephrology, Topiwala National Medical College and B. Y. L. Nair Charitable Hospital, Mumbai, Maharashtra, India
| | - S. Bhurke
- Department of Nephrology, Topiwala National Medical College and B. Y. L. Nair Charitable Hospital, Mumbai, Maharashtra, India
| | - A. Shirkande
- Department of Nephrology, Topiwala National Medical College and B. Y. L. Nair Charitable Hospital, Mumbai, Maharashtra, India
| | - R. Bhadade
- Department of Medicine, Topiwala National Medical College and B. Y. L. Nair Charitable Hospital, Mumbai, Maharashtra, India
| | - R. D'Souza
- Department of Medicine, Topiwala National Medical College and B. Y. L. Nair Charitable Hospital, Mumbai, Maharashtra, India
| |
Collapse
|
19
|
Villegas SL, Darb-Esfahani S, von Minckwitz G, Huober J, Weber K, Marmé F, Furlanetto J, Schem C, Pfitzner BM, Lederer B, Engels K, Kümmel S, Müller V, Mehta K, Denkert C, Loibl S. Expression of Cyclin D1 protein in residual tumor after neoadjuvant chemotherapy for breast cancer. Breast Cancer Res Treat 2017; 168:179-187. [PMID: 29177689 DOI: 10.1007/s10549-017-4581-1] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/28/2017] [Accepted: 11/15/2017] [Indexed: 10/18/2022]
Abstract
PURPOSE Hormone receptor (HR)-positive breast cancer (BC) shows a poor response to neoadjuvant chemotherapy (NACT). New treatment targets like the Cyclin D1-CDK4/CDK6 complex are promising adjuvant/post-neoadjuvant therapeutic strategies. Evaluating Cyclin D1 overexpression in residual tumor could recognize those patients that benefit most from such post-neoadjuvant treatment. In this study, we determined Cyclin D1 expression in residual BC after NACT. Secondary aims were to correlate Cyclin D1 expression levels with clinicopathological parameters and to assess its prognostic value after NACT. METHODS We retrospectively assessed the nuclear expression of Cyclin D1 on tissue microarrays with residual tumor from 284 patients treated in the neoadjuvant GeparTrio (n = 186) and GeparQuattro (n = 98) trials. Evaluation was performed with a standardized immunoreactive score (IRS) after selecting a cut-off value. RESULTS A high expression level (IRS ≥ 6) of Cyclin D1 was found in 37.3% of the assessed specimens. An increased Cyclin D1 expression was observed in HR-positive tumors, compared to HR-negative tumors (p = 0.02). Low Cyclin D1 levels correlated with clinical tumor stage 1-3 (p = 0.03). Among patients with HR-positive/Her2-negative tumors and high Cyclin D1 expression, a better disease-free survival (DFS) was graphically suggested, but not significant (p = 0.21). CONCLUSION Our study demonstrates a measurable nuclear expression of Cyclin D1 in post-neoadjuvant residual tumor tissue of HR-positive BC. Cyclin D1 expression was not prognostic for DFS after NACT. Our results and defined cut-off suggest that the marker can be used to stratify tumors according to protein expression levels. Based on this, a prospective evaluation is currently performed in the ongoing Penelope-B trial.
Collapse
Affiliation(s)
- S L Villegas
- Institute of Pathology, Charité Universitätsmedizin Berlin, Charitéplatz 1, 10117, Berlin, Germany
| | - S Darb-Esfahani
- Institute of Pathology, Charité Universitätsmedizin Berlin, Charitéplatz 1, 10117, Berlin, Germany.,Institute of Pathology Spandau, Evangelisches Waldkrankenhaus, Stadtrandstr. 555, 13589, Berlin, Germany
| | - G von Minckwitz
- German Breast Group (GBG Forschungs GmbH), Martin-Behaim-Str. 12, 63263, Neu-Isenburg, Germany
| | - J Huober
- Department of Obstetrics and Gynecology, Ulm University, Ulm, Germany
| | - K Weber
- German Breast Group (GBG Forschungs GmbH), Martin-Behaim-Str. 12, 63263, Neu-Isenburg, Germany
| | - F Marmé
- National Center for Tumor Diseases, University-Hospital Heidelberg, Im Neuenheimer Feld 460, 69120, Heidelberg, Germany
| | - J Furlanetto
- German Breast Group (GBG Forschungs GmbH), Martin-Behaim-Str. 12, 63263, Neu-Isenburg, Germany
| | - C Schem
- Department of Gynecology and Obstetrics, University Hospital Schleswig-Hostein, Kiel, Germany
| | - B M Pfitzner
- Institute of Pathology, Charité Universitätsmedizin Berlin, Charitéplatz 1, 10117, Berlin, Germany
| | - B Lederer
- German Breast Group (GBG Forschungs GmbH), Martin-Behaim-Str. 12, 63263, Neu-Isenburg, Germany
| | - K Engels
- Zentrum für Pathologie, Zytologie und Molekularpathologie Neuss, Neuss, Germany
| | - S Kümmel
- Breast Unit Kliniken Essen-Mitte, Essen, Germany
| | - V Müller
- Department of Gynecology, University Medical Center Hamburg-Eppendorf, 20246, Hamburg, Germany
| | - K Mehta
- German Breast Group (GBG Forschungs GmbH), Martin-Behaim-Str. 12, 63263, Neu-Isenburg, Germany
| | - C Denkert
- Institute of Pathology, Charité Universitätsmedizin Berlin, Charitéplatz 1, 10117, Berlin, Germany. .,German Cancer Consortium (DKTK), Partner Site Charité, Berlin, Germany.
| | - S Loibl
- German Breast Group (GBG Forschungs GmbH), Martin-Behaim-Str. 12, 63263, Neu-Isenburg, Germany
| |
Collapse
|
20
|
Yeo G, Hikoyeda N, McBride M, Tzuang M, Grudzen M, Mehta K. FACULTY DEVELOPMENT IN ETHNOGERIATRICS. Innov Aging 2017. [DOI: 10.1093/geroni/igx004.766] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
Affiliation(s)
- G. Yeo
- Stanford University, Stanford, California,
| | | | | | - M. Tzuang
- Stanford University, Stanford, California,
- Johns Hopkins University, Baltimore, Maryland
| | | | - K. Mehta
- Stanford University, Stanford, California,
- University of California, San Francisco, San Francisco, California,
| |
Collapse
|
21
|
Miller E, Viswanathan S, Li S, Mehta K, Smith H, Smotkin D, Kuo D, Goldberg G, Einstein M, Frimer M. Adjuvant pelvic radiation sandwiched between paclitaxel/carboplatin chemotherapy in women with completely resected uterine serous carcinoma (USC): A prospective phase II trial update. Gynecol Oncol 2017. [DOI: 10.1016/j.ygyno.2017.03.159] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/19/2022]
|
22
|
Lindauer A, Valiathan CR, Mehta K, Sriram V, de Greef R, Elassaiss-Schaap J, de Alwis DP. Translational Pharmacokinetic/Pharmacodynamic Modeling of Tumor Growth Inhibition Supports Dose-Range Selection of the Anti-PD-1 Antibody Pembrolizumab. CPT Pharmacometrics Syst Pharmacol 2016; 6:11-20. [PMID: 27863176 PMCID: PMC5270293 DOI: 10.1002/psp4.12130] [Citation(s) in RCA: 79] [Impact Index Per Article: 9.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Received: 03/23/2016] [Accepted: 08/29/2016] [Indexed: 12/30/2022]
Abstract
Pembrolizumab, a humanized monoclonal antibody against programmed death 1 (PD‐1), has a manageable safety profile and robust clinical activity against advanced malignancies. The lowest effective dose for evaluation in further dose‐ranging studies was identified by developing a translational model from preclinical mouse experiments. A compartmental pharmacokinetic model was combined with a published physiologically based tissue compartment, linked to receptor occupancy as the driver of observed tumor growth inhibition. Human simulations were performed using clinical pharmacokinetic data, literature values, and in vitro parameters for drug distribution and binding. Biological and mathematical uncertainties were included in simulations to generate expectations for dose response. The results demonstrated a minimal increase in efficacy for doses higher than 2 mg/kg. The findings of the translational model were successfully applied to select 2 mg/kg as the lowest dose for dose‐ranging evaluations.
Collapse
Affiliation(s)
- A Lindauer
- Merck & Co., Inc., Rahway, New Jersey, USA
| | | | - K Mehta
- Merck & Co., Inc., Rahway, New Jersey, USA
| | - V Sriram
- Merck & Co., Inc., Rahway, New Jersey, USA
| | - R de Greef
- Merck & Co., Inc., Rahway, New Jersey, USA
| | | | | |
Collapse
|
23
|
Dadayal G, Weston M, Young A, Graham J, Mehta K, Wilkinson N, Spencer J. Transvaginal ultrasound (TVUS)-guided biopsy is safe and effective in diagnosing peritoneal carcinomatosis and recurrent pelvic malignancy. Clin Radiol 2016; 71:1184-92. [DOI: 10.1016/j.crad.2016.06.119] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/28/2015] [Revised: 05/08/2016] [Accepted: 06/23/2016] [Indexed: 11/29/2022]
|
24
|
Jindal RM, Soni R, Mehta K, Patel TG. Incidence of diabetes and hypertension in indigenous Amerindian village in Guyana, South America. Indian J Nephrol 2016; 26:389-390. [PMID: 27795642 PMCID: PMC5015526 DOI: 10.4103/0971-4065.181471] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/17/2022] Open
Affiliation(s)
- R M Jindal
- Department of Surgery and Preventative Medicine and Biostatistics, Uniformed Services University of the Health Sciences and Walter Reed NNMC, Bethesda, MD, USA
| | - R Soni
- Department of Medicine, Central Michigan University College of Medicine, Saginaw, MI, USA
| | - K Mehta
- Department of Medicine, University of Pittsburgh Medical Center, Pittsburgh, PA, USA
| | - T G Patel
- Department of Medicine, Uniformed Service University, Bethesda, MD, USA
| |
Collapse
|
25
|
von Minckwitz G, Rezai M, Tesch H, Huober J, Gerber B, Zahm D, Hilfrich J, Costa S, Dubsky P, Blohmer J, Denkert C, Hanusch C, Jackisch C, Kümmel S, Fasching P, Schneeweiss A, Paepke S, Untch M, Burchardi N, Mehta K, Loibl S. Zoledronate for patients with invasive residual disease after anthracyclines-taxane-based chemotherapy for early breast cancer – The Phase III NeoAdjuvant Trial Add-oN (NaTaN) study (GBG 36/ABCSG 29). Eur J Cancer 2016; 64:12-21. [DOI: 10.1016/j.ejca.2016.05.015] [Citation(s) in RCA: 21] [Impact Index Per Article: 2.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/10/2016] [Revised: 04/27/2016] [Accepted: 05/14/2016] [Indexed: 11/25/2022]
|
26
|
Hoyler E, Martinez R, Mehta K, Nisonoff H, Boyd D. Beyond medical pluralism: characterising health-care delivery of biomedicine and traditional medicine in rural Guatemala. Glob Public Health 2016; 13:503-517. [PMID: 27416306 DOI: 10.1080/17441692.2016.1207197] [Citation(s) in RCA: 10] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/21/2022]
Abstract
Although approximately one half of Guatemalans are indigenous, the Guatemalan Maya account for 72% of the extremely poor within the country. While some biomedical services are available in these communities, many Maya utilise traditional medicine as a significant, if not primary, source of health care. While existing medical anthropological research characterises these modes of medicine as medically dichotomous or pluralistic, our research in a Maya community of the Western Highlands, Concepción Huista, builds on previous studies and finds instead a syncretistic, imbricated local health system. We find significant overlap and interpenetration of the biomedical and traditional medical models that are described best as a framework where practitioners in both settings employ elements of the other in order to best meet community needs. By focusing on the practitioner's perspective, we demonstrate that in addition to patients' willingness to seek care across health systems, practitioners converse across seemingly distinct systems via incorporation of certain elements of the 'other'. Interventions to date have not accounted for this imbrication. Guatemalan governmental policies to support local healers have led to little practical change in the health-care landscape of the country. Therefore, understanding this complex imbrication is crucial for interventions and policy changes.
Collapse
Affiliation(s)
- Elizabeth Hoyler
- a Duke Global Health Institute, Duke University , Durham , NC , USA
| | - Roxana Martinez
- a Duke Global Health Institute, Duke University , Durham , NC , USA
| | - Kurren Mehta
- a Duke Global Health Institute, Duke University , Durham , NC , USA
| | - Hunter Nisonoff
- a Duke Global Health Institute, Duke University , Durham , NC , USA
| | - David Boyd
- a Duke Global Health Institute, Duke University , Durham , NC , USA
| |
Collapse
|
27
|
Jindal RM, Mehta K, Soni R, Doyle A, Patel TG. Diabetes, hypertension, sanitation, and health education by high school students in Guyana, South America. Indian J Nephrol 2016; 26:192-8. [PMID: 27194834 PMCID: PMC4862265 DOI: 10.4103/0971-4065.161522] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/05/2022] Open
Abstract
We initiated a program for early detection of diabetes and hypertension, the main causes of kidney failure in Guyana, South America. We trained local high school students with the goal that these students would stay in the villages for long-term, become health advocates and shift the reliance away from physicians. This project involved 7 high school students who were taught to monitor the health of one village of 1000–1500 population each. The program will be implemented for 3 years in which the entire population of seven villages (approximately 10,000 people) will be covered. This represents 1.3% population in Guyana. We present data from the pilot study from the sample of 619 people. The prevalence of diabetes mellitus was 13.9%. Among diabetics, 33.7% were using insulin and 86% oral hypoglycemic agents. Prevalence of hypertension was 29.4%, 63.2% were overweight and 17% were obese. About 9.9% patients were unaware about the existence of hypertension. We have shown in our study that high school students can be used to collect health data and monitor diabetes and hypertension. There was also a significant incidence of undetected diabetes and hypertension.
Collapse
Affiliation(s)
- R M Jindal
- Department of Surgery, Division of Global Health, Uniformed Services University of the Health Sciences, Bethesda, MD; Department of Medicine and Surgery, The George Washington University, Washington, DC, USA
| | - K Mehta
- Department of Medicine, University of Pittsburgh Medical Center, Pittsburgh, USA
| | - R Soni
- Department of Medicine, Central Michigan University College of Medicine, Saginaw, MI, USA
| | - A Doyle
- Department of Medicine, Drexel University School of Medicine, Philadelphia, PA, USA
| | - T G Patel
- Department of Medicine, Uniformed Services University of the Health Sciences, Bethesda, MD, USA
| |
Collapse
|
28
|
Mehta K, Narreddy S, Rao S N. Congenital Syphilis: Complicating an already complex adoption process. Int J Infect Dis 2016. [DOI: 10.1016/j.ijid.2016.02.734] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/24/2022] Open
|
29
|
Denkert C, Budczies J, Regan M, Loibl S, Dell'Orto P, von Minckwitz G, Mastropasqua M, Mehta K, Müller V, Kammler R, Pfitzner BM, Fasching PA, Viale G. Abstract P5-07-02: Systematic analysis and modulation of Ki67 interobserver variance in 9069 patients from three clinical trials – How much pathologist concordance is needed for meaningful biomarker results? Cancer Res 2016. [DOI: 10.1158/1538-7445.sabcs15-p5-07-02] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Background: Ki67 has been suggested as a marker for diagnosis of luminal A and B breast carcinomas. Interestingly, on one hand a multitude of studies have described significant results for Ki67 as a prognostic marker, while on the other hand the analytical validation and standardization of this marker has been a challenge. The best parameter for Ki67 interobserver performance is the interclass correlation coefficient (ICC). ICC values between 0.59 and 0.92 have been reported. Recently a minimum ICC of 0.8 has been suggested as a goal for the international ring trial and as a prerequisite for introduction of Ki67 into clinical practice. However, this suggested ICC is not derived from analysis of data, and the amount of pathologist variance that is allowed for meaningful biomarker results is still not defined.
Methods: This study is based on a total of 9069 tumor samples from three large clinical cohorts (IBCSG VIII+IX, BIG1-98, and GeparTrio). In a systematic modeling approach, we introduced different amounts of variance to previously generated central pathology Ki67 datasets by simulation of a total of 1800 different pathologist evaluations for each study cohort. These evaluations were grouped into groups with defined ICCs, ranging from very good concordance (ICC=0.9) to extremely poor concordance (ICC=0.1). For each of the simulated pathologist evaluations, all possible Ki67 cutoffs were systematically evaluated using the web-based software Cutoff Finder (http://molpath.charite.de/cutoff/). As endpoints, we used DFS for all three study cohorts as well as pCR for the neoadjuvant cohort.
Results: For the neoadjuvant GeparTrio study, the different groups with ICCs of 0.8, 0.6 and 0.4 showed a very similar performance resulting in significant analyses for prediction of pCR across a wide range of cutoffs. The odd ratios for pCR were slightly lower with lower ICC. Even with an extremely low ICC of 0.2, 99% of the analyses had one or more significant cutpoints.
The survival endpoint DFS was shown to be very stable despite increased interpathologist variance in all three clinical cohorts. Even with a poor ICC of 0.4, the majority of cutpoints were significant for DFS. For IBCSG VIII+IX 85% of the analyses with an ICC of 0.4 had one or more significant cutpoints for Ki67. In the large BIG 1-98 dataset (n=6090) even an ICC of 0.2 resulted in one or more significant DFS cutpoints in 100% of the analyses. Comparable results were obtained if the analysis was restricted to luminal tumors.
Conclusion: Our results suggest that Ki67 is extremely robust to pathologist variation. Even if less than 40% of the variance is attributable to true Ki67-based proliferation (ICC<0.4), this percentage of information is sufficient to obtain statistically significant differences. This stable performance of Ki67 might provide an explanation for the observation that many Ki67 studies achieve significant results despite the interobserver variance and heterogeneity issues. It might also suggest a relevant clinical utility for Ki67 despite considerable variation introduced in the evaluation. Ongoing efforts to further reduce interobserver variability, however, should be continued.
Citation Format: Denkert C, Budczies J, Regan M, Loibl S, Dell'Orto P, von Minckwitz G, Mastropasqua M, Mehta K, Müller V, Kammler R, Pfitzner BM, Fasching PA, Viale G. Systematic analysis and modulation of Ki67 interobserver variance in 9069 patients from three clinical trials – How much pathologist concordance is needed for meaningful biomarker results?. [abstract]. In: Proceedings of the Thirty-Eighth Annual CTRC-AACR San Antonio Breast Cancer Symposium: 2015 Dec 8-12; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2016;76(4 Suppl):Abstract nr P5-07-02.
Collapse
Affiliation(s)
- C Denkert
- Charité University Hospital - Institute of Pathology, Berlin, Germany; Dana-Farber Cancer Institute, Boston; German Breast Group, Neu-Isenburg, Germany; Istituto Europeo di Oncologia, Milano, Italy; Universitätsklinikum Eppendorf, Hamburg, Germany; IBCSG Coordinating Center, Bern, Switzerland; University of Erlangen, Erlangen, Germany
| | - J Budczies
- Charité University Hospital - Institute of Pathology, Berlin, Germany; Dana-Farber Cancer Institute, Boston; German Breast Group, Neu-Isenburg, Germany; Istituto Europeo di Oncologia, Milano, Italy; Universitätsklinikum Eppendorf, Hamburg, Germany; IBCSG Coordinating Center, Bern, Switzerland; University of Erlangen, Erlangen, Germany
| | - M Regan
- Charité University Hospital - Institute of Pathology, Berlin, Germany; Dana-Farber Cancer Institute, Boston; German Breast Group, Neu-Isenburg, Germany; Istituto Europeo di Oncologia, Milano, Italy; Universitätsklinikum Eppendorf, Hamburg, Germany; IBCSG Coordinating Center, Bern, Switzerland; University of Erlangen, Erlangen, Germany
| | - S Loibl
- Charité University Hospital - Institute of Pathology, Berlin, Germany; Dana-Farber Cancer Institute, Boston; German Breast Group, Neu-Isenburg, Germany; Istituto Europeo di Oncologia, Milano, Italy; Universitätsklinikum Eppendorf, Hamburg, Germany; IBCSG Coordinating Center, Bern, Switzerland; University of Erlangen, Erlangen, Germany
| | - P Dell'Orto
- Charité University Hospital - Institute of Pathology, Berlin, Germany; Dana-Farber Cancer Institute, Boston; German Breast Group, Neu-Isenburg, Germany; Istituto Europeo di Oncologia, Milano, Italy; Universitätsklinikum Eppendorf, Hamburg, Germany; IBCSG Coordinating Center, Bern, Switzerland; University of Erlangen, Erlangen, Germany
| | - G von Minckwitz
- Charité University Hospital - Institute of Pathology, Berlin, Germany; Dana-Farber Cancer Institute, Boston; German Breast Group, Neu-Isenburg, Germany; Istituto Europeo di Oncologia, Milano, Italy; Universitätsklinikum Eppendorf, Hamburg, Germany; IBCSG Coordinating Center, Bern, Switzerland; University of Erlangen, Erlangen, Germany
| | - M Mastropasqua
- Charité University Hospital - Institute of Pathology, Berlin, Germany; Dana-Farber Cancer Institute, Boston; German Breast Group, Neu-Isenburg, Germany; Istituto Europeo di Oncologia, Milano, Italy; Universitätsklinikum Eppendorf, Hamburg, Germany; IBCSG Coordinating Center, Bern, Switzerland; University of Erlangen, Erlangen, Germany
| | - K Mehta
- Charité University Hospital - Institute of Pathology, Berlin, Germany; Dana-Farber Cancer Institute, Boston; German Breast Group, Neu-Isenburg, Germany; Istituto Europeo di Oncologia, Milano, Italy; Universitätsklinikum Eppendorf, Hamburg, Germany; IBCSG Coordinating Center, Bern, Switzerland; University of Erlangen, Erlangen, Germany
| | - V Müller
- Charité University Hospital - Institute of Pathology, Berlin, Germany; Dana-Farber Cancer Institute, Boston; German Breast Group, Neu-Isenburg, Germany; Istituto Europeo di Oncologia, Milano, Italy; Universitätsklinikum Eppendorf, Hamburg, Germany; IBCSG Coordinating Center, Bern, Switzerland; University of Erlangen, Erlangen, Germany
| | - R Kammler
- Charité University Hospital - Institute of Pathology, Berlin, Germany; Dana-Farber Cancer Institute, Boston; German Breast Group, Neu-Isenburg, Germany; Istituto Europeo di Oncologia, Milano, Italy; Universitätsklinikum Eppendorf, Hamburg, Germany; IBCSG Coordinating Center, Bern, Switzerland; University of Erlangen, Erlangen, Germany
| | - BM Pfitzner
- Charité University Hospital - Institute of Pathology, Berlin, Germany; Dana-Farber Cancer Institute, Boston; German Breast Group, Neu-Isenburg, Germany; Istituto Europeo di Oncologia, Milano, Italy; Universitätsklinikum Eppendorf, Hamburg, Germany; IBCSG Coordinating Center, Bern, Switzerland; University of Erlangen, Erlangen, Germany
| | - PA Fasching
- Charité University Hospital - Institute of Pathology, Berlin, Germany; Dana-Farber Cancer Institute, Boston; German Breast Group, Neu-Isenburg, Germany; Istituto Europeo di Oncologia, Milano, Italy; Universitätsklinikum Eppendorf, Hamburg, Germany; IBCSG Coordinating Center, Bern, Switzerland; University of Erlangen, Erlangen, Germany
| | - G Viale
- Charité University Hospital - Institute of Pathology, Berlin, Germany; Dana-Farber Cancer Institute, Boston; German Breast Group, Neu-Isenburg, Germany; Istituto Europeo di Oncologia, Milano, Italy; Universitätsklinikum Eppendorf, Hamburg, Germany; IBCSG Coordinating Center, Bern, Switzerland; University of Erlangen, Erlangen, Germany
| |
Collapse
|
30
|
|
31
|
Singh S, Pokharel P, Raut P, Mehta K. Study of the effects of pesticide exposure among the workers of tea
estates. Ann Glob Health 2015. [DOI: 10.1016/j.aogh.2015.02.1026] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/23/2022] Open
|
32
|
Hong M, Bendavid E, Mehta K. HealthTrax: A new tool to identify and navigate dirt roads for health
outreach work in Southern Zambia. Ann Glob Health 2015. [DOI: 10.1016/j.aogh.2015.02.939] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022] Open
|
33
|
Mehta K, Soderblom EJ, Thompson JW, Que LG, Marshall HE, Moseley MA, Foster MW. Targeted proteomics for unraveling the post-translational regulation of human nitric oxide synthase 2. Nitric Oxide 2014. [DOI: 10.1016/j.niox.2014.09.100] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/24/2022]
|
34
|
Kuo H, Tome W, FOX J, Hong L, Yaparpalvi R, Mehta K, Huang Y, Bodner W, Kalnicki S. TU-F-18C-09: Mammogram Surveillance Using Texture Analysis for Breast Cancer Patients After Radiation Therapy. Med Phys 2014. [DOI: 10.1118/1.4889354] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/07/2022] Open
|
35
|
Abstract
The findings of the 4 preceding country studies are examined here from a comparative perspective identifying some of the similarities and differences that underlie living arrangements of the elderly. More specifically, we compare the normative basis underlying living arrangements, mechanisms that help perpetuate co-residence, strains inherent to co-residence, preferences for co-residents, alternative forms of living arrangements, and views of social changes in relation to living arrangements. Overall, the focus group data on which the studies are based highlight the importance of culture in influencing the living arrangements of elderly people in Asia. The results suggest that at least for the next generation, co-residential living by elderly with children will continue to be a viable option, although the extent to which it persists is likely to vary among the 4 countries studied.
Collapse
Affiliation(s)
- M M Asis
- Department of Sociology, University of the Philippines, Dilman, 1101, Quexon City, Philippines
| | | | | | | |
Collapse
|
36
|
Cortazar P, Zhang L, Untch M, Mehta K, Constantino J, Wolmark N, Bonnefoi H, Piccart M, Gianni L, Valagussa P, Zujewski JA, Justice R, Loibl S, Swain SM, Bogaerts J, Baselga J, Prowell TM, Rastogi P, Sridhara R, Tang S, Pazdur R, Mamounas E, von Minckwitz G. Abstract P5-17-01: A definition of a high-risk early-breast cancer population based on data from the collaborative trials in neoadjuvant breast cancer (CTNeoBC) meta-analysis. Cancer Res 2013. [DOI: 10.1158/0008-5472.sabcs13-p5-17-01] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Background: Pathological complete response (pCR) is a proposed surrogate endpoint for predicting long-term clinical benefit on endpoints such as event-free survival (EFS) or overall survival (OS). The CTNeoBC meta-analysis did not validate the surrogacy of pCR for EFS or OS, and there is no precedent for its use as a regulatory endpoint in oncology. Use of the accelerated approval pathway has been proposed for neoadjuvant therapies that substantially improve pCR as a means to expedite widespread access to highly effective therapies for high-risk, early breast cancer. Potential risks of this approach include approving an agent that ultimately does not demonstrate clinical benefit and, in the interim, exposing curable patients to the toxicity of therapy without certainty of benefit. To mitigate the risks of this pathway, enrollment to neoadjuvant trials intended to support accelerated approval should be restricted to patients presenting with high-risk early-stage breast cancer. The 5-year EFS rate by breast cancer subtype in the CTNeoBC meta-analysis population is presented. Methods: We identified 12 neoadjuvant randomized trials (N = 12,993) with pCR clearly defined and long-term follow-up available for EFS and OS. Trials included AGO 1 (n = 668), ECTO (n = 1355), EORTC 10994/BIG 1-00 (n = 1856), GeparDuo (n = 907), GeparQuattro (n = 1495), GeparTrio (n = 2072), GeparTrio-Pilot (n = 285), NOAH (n = 234), NSABP B18 (n = 760), NSABP B27 (n = 2411), PREPARE (n = 733), and TECHNO (n = 217). The key objective of this analysis was to establish a definition of “high-risk” based on the Kaplan-Meier estimates of the 5-year EFS rate in the different clinical breast cancer subtypes (hormone receptor-positive, HER2-positive and triple-negative) analyzed by tumor stage and tumor grade at presentation. Results: The 5-year EFS rate was less than 65% in all the breast cancer subtypes with stage III disease. For patients with stage II disease, the impact of tumor grade varied by hormone receptor status. Patients with hormone receptor-negative breast cancer, regardless of HER2 status had a poor prognosis that was independent of tumor grade. For patients with hormone receptor-positive tumors, regardless of HER2 status, high grade histology was associated with an increased risk of recurrence.
5-year Event-Free Survival Rate (EFS) 5-year EFS Rate Estimate (95% confidence interval)TNMStage IIStage III Grade IIGrade IIIGrade IIGrade IIIHormone Receptor + HER2-83% (80%, 85%)71% (65%, 77%)63% (58%, 69%)51% (42%, 59%)HER2+ HR+81% (75%, 86%)69% (60%, 76%)50% (41%, 59%)48% (37%, 59%)HER2+ HR-61% (51%, 70%)66% (57%, 73%)58% (46%, 69%)46% (36%, 55%)Triple Negative66% (58%, 72%)72% (67%, 76%)38% (27%, 48%)37% (29%, 45%)
Conclusions: This analysis estimated the 5-year EFS rate in the breast cancer subtypes from the CTNeoBC meta-analysis population. The HER2-positive population in the meta-analysis was at particularly high risk because most of the patients had locally advanced breast cancer and only 39% of these patients received trastuzumab therapy. We propose defining less than 75% 5-year EFS rate as “high-risk” for the purposes of designing neoadjuvant trials that intend to use pCR to support accelerated approval.
Citation Information: Cancer Res 2013;73(24 Suppl): Abstract nr P5-17-01.
Collapse
Affiliation(s)
- P Cortazar
- FDA; HELIOS Klinikum Berlin-Buch, Berlin, Germany, D-13125; GBG Forschungs GmbH, Germany; NSABP, Pittsburgh, PA; Institut Bergonié, INSERM U916; Jules Bordet Institute, Brussels, Belgium; San Raffaele Scientific Insitute, Milan, Italy; Fondazione Michelangelo, Milan, Italy; Cancer Therapy Evaluation Program, NCI, Bethesda, MD; Medstar Washington Hospital Center, Washington, DC; EORTC Headquarters, Brussels, Belgium; Memorial Sloan-Kettering Cancer Center, New York; Orlando Health MD Anderson Cancer Center
| | - L Zhang
- FDA; HELIOS Klinikum Berlin-Buch, Berlin, Germany, D-13125; GBG Forschungs GmbH, Germany; NSABP, Pittsburgh, PA; Institut Bergonié, INSERM U916; Jules Bordet Institute, Brussels, Belgium; San Raffaele Scientific Insitute, Milan, Italy; Fondazione Michelangelo, Milan, Italy; Cancer Therapy Evaluation Program, NCI, Bethesda, MD; Medstar Washington Hospital Center, Washington, DC; EORTC Headquarters, Brussels, Belgium; Memorial Sloan-Kettering Cancer Center, New York; Orlando Health MD Anderson Cancer Center
| | - M Untch
- FDA; HELIOS Klinikum Berlin-Buch, Berlin, Germany, D-13125; GBG Forschungs GmbH, Germany; NSABP, Pittsburgh, PA; Institut Bergonié, INSERM U916; Jules Bordet Institute, Brussels, Belgium; San Raffaele Scientific Insitute, Milan, Italy; Fondazione Michelangelo, Milan, Italy; Cancer Therapy Evaluation Program, NCI, Bethesda, MD; Medstar Washington Hospital Center, Washington, DC; EORTC Headquarters, Brussels, Belgium; Memorial Sloan-Kettering Cancer Center, New York; Orlando Health MD Anderson Cancer Center
| | - K Mehta
- FDA; HELIOS Klinikum Berlin-Buch, Berlin, Germany, D-13125; GBG Forschungs GmbH, Germany; NSABP, Pittsburgh, PA; Institut Bergonié, INSERM U916; Jules Bordet Institute, Brussels, Belgium; San Raffaele Scientific Insitute, Milan, Italy; Fondazione Michelangelo, Milan, Italy; Cancer Therapy Evaluation Program, NCI, Bethesda, MD; Medstar Washington Hospital Center, Washington, DC; EORTC Headquarters, Brussels, Belgium; Memorial Sloan-Kettering Cancer Center, New York; Orlando Health MD Anderson Cancer Center
| | - J Constantino
- FDA; HELIOS Klinikum Berlin-Buch, Berlin, Germany, D-13125; GBG Forschungs GmbH, Germany; NSABP, Pittsburgh, PA; Institut Bergonié, INSERM U916; Jules Bordet Institute, Brussels, Belgium; San Raffaele Scientific Insitute, Milan, Italy; Fondazione Michelangelo, Milan, Italy; Cancer Therapy Evaluation Program, NCI, Bethesda, MD; Medstar Washington Hospital Center, Washington, DC; EORTC Headquarters, Brussels, Belgium; Memorial Sloan-Kettering Cancer Center, New York; Orlando Health MD Anderson Cancer Center
| | - N Wolmark
- FDA; HELIOS Klinikum Berlin-Buch, Berlin, Germany, D-13125; GBG Forschungs GmbH, Germany; NSABP, Pittsburgh, PA; Institut Bergonié, INSERM U916; Jules Bordet Institute, Brussels, Belgium; San Raffaele Scientific Insitute, Milan, Italy; Fondazione Michelangelo, Milan, Italy; Cancer Therapy Evaluation Program, NCI, Bethesda, MD; Medstar Washington Hospital Center, Washington, DC; EORTC Headquarters, Brussels, Belgium; Memorial Sloan-Kettering Cancer Center, New York; Orlando Health MD Anderson Cancer Center
| | - H Bonnefoi
- FDA; HELIOS Klinikum Berlin-Buch, Berlin, Germany, D-13125; GBG Forschungs GmbH, Germany; NSABP, Pittsburgh, PA; Institut Bergonié, INSERM U916; Jules Bordet Institute, Brussels, Belgium; San Raffaele Scientific Insitute, Milan, Italy; Fondazione Michelangelo, Milan, Italy; Cancer Therapy Evaluation Program, NCI, Bethesda, MD; Medstar Washington Hospital Center, Washington, DC; EORTC Headquarters, Brussels, Belgium; Memorial Sloan-Kettering Cancer Center, New York; Orlando Health MD Anderson Cancer Center
| | - M Piccart
- FDA; HELIOS Klinikum Berlin-Buch, Berlin, Germany, D-13125; GBG Forschungs GmbH, Germany; NSABP, Pittsburgh, PA; Institut Bergonié, INSERM U916; Jules Bordet Institute, Brussels, Belgium; San Raffaele Scientific Insitute, Milan, Italy; Fondazione Michelangelo, Milan, Italy; Cancer Therapy Evaluation Program, NCI, Bethesda, MD; Medstar Washington Hospital Center, Washington, DC; EORTC Headquarters, Brussels, Belgium; Memorial Sloan-Kettering Cancer Center, New York; Orlando Health MD Anderson Cancer Center
| | - L Gianni
- FDA; HELIOS Klinikum Berlin-Buch, Berlin, Germany, D-13125; GBG Forschungs GmbH, Germany; NSABP, Pittsburgh, PA; Institut Bergonié, INSERM U916; Jules Bordet Institute, Brussels, Belgium; San Raffaele Scientific Insitute, Milan, Italy; Fondazione Michelangelo, Milan, Italy; Cancer Therapy Evaluation Program, NCI, Bethesda, MD; Medstar Washington Hospital Center, Washington, DC; EORTC Headquarters, Brussels, Belgium; Memorial Sloan-Kettering Cancer Center, New York; Orlando Health MD Anderson Cancer Center
| | - P Valagussa
- FDA; HELIOS Klinikum Berlin-Buch, Berlin, Germany, D-13125; GBG Forschungs GmbH, Germany; NSABP, Pittsburgh, PA; Institut Bergonié, INSERM U916; Jules Bordet Institute, Brussels, Belgium; San Raffaele Scientific Insitute, Milan, Italy; Fondazione Michelangelo, Milan, Italy; Cancer Therapy Evaluation Program, NCI, Bethesda, MD; Medstar Washington Hospital Center, Washington, DC; EORTC Headquarters, Brussels, Belgium; Memorial Sloan-Kettering Cancer Center, New York; Orlando Health MD Anderson Cancer Center
| | - JA Zujewski
- FDA; HELIOS Klinikum Berlin-Buch, Berlin, Germany, D-13125; GBG Forschungs GmbH, Germany; NSABP, Pittsburgh, PA; Institut Bergonié, INSERM U916; Jules Bordet Institute, Brussels, Belgium; San Raffaele Scientific Insitute, Milan, Italy; Fondazione Michelangelo, Milan, Italy; Cancer Therapy Evaluation Program, NCI, Bethesda, MD; Medstar Washington Hospital Center, Washington, DC; EORTC Headquarters, Brussels, Belgium; Memorial Sloan-Kettering Cancer Center, New York; Orlando Health MD Anderson Cancer Center
| | - R Justice
- FDA; HELIOS Klinikum Berlin-Buch, Berlin, Germany, D-13125; GBG Forschungs GmbH, Germany; NSABP, Pittsburgh, PA; Institut Bergonié, INSERM U916; Jules Bordet Institute, Brussels, Belgium; San Raffaele Scientific Insitute, Milan, Italy; Fondazione Michelangelo, Milan, Italy; Cancer Therapy Evaluation Program, NCI, Bethesda, MD; Medstar Washington Hospital Center, Washington, DC; EORTC Headquarters, Brussels, Belgium; Memorial Sloan-Kettering Cancer Center, New York; Orlando Health MD Anderson Cancer Center
| | - S Loibl
- FDA; HELIOS Klinikum Berlin-Buch, Berlin, Germany, D-13125; GBG Forschungs GmbH, Germany; NSABP, Pittsburgh, PA; Institut Bergonié, INSERM U916; Jules Bordet Institute, Brussels, Belgium; San Raffaele Scientific Insitute, Milan, Italy; Fondazione Michelangelo, Milan, Italy; Cancer Therapy Evaluation Program, NCI, Bethesda, MD; Medstar Washington Hospital Center, Washington, DC; EORTC Headquarters, Brussels, Belgium; Memorial Sloan-Kettering Cancer Center, New York; Orlando Health MD Anderson Cancer Center
| | - SM Swain
- FDA; HELIOS Klinikum Berlin-Buch, Berlin, Germany, D-13125; GBG Forschungs GmbH, Germany; NSABP, Pittsburgh, PA; Institut Bergonié, INSERM U916; Jules Bordet Institute, Brussels, Belgium; San Raffaele Scientific Insitute, Milan, Italy; Fondazione Michelangelo, Milan, Italy; Cancer Therapy Evaluation Program, NCI, Bethesda, MD; Medstar Washington Hospital Center, Washington, DC; EORTC Headquarters, Brussels, Belgium; Memorial Sloan-Kettering Cancer Center, New York; Orlando Health MD Anderson Cancer Center
| | - J Bogaerts
- FDA; HELIOS Klinikum Berlin-Buch, Berlin, Germany, D-13125; GBG Forschungs GmbH, Germany; NSABP, Pittsburgh, PA; Institut Bergonié, INSERM U916; Jules Bordet Institute, Brussels, Belgium; San Raffaele Scientific Insitute, Milan, Italy; Fondazione Michelangelo, Milan, Italy; Cancer Therapy Evaluation Program, NCI, Bethesda, MD; Medstar Washington Hospital Center, Washington, DC; EORTC Headquarters, Brussels, Belgium; Memorial Sloan-Kettering Cancer Center, New York; Orlando Health MD Anderson Cancer Center
| | - J Baselga
- FDA; HELIOS Klinikum Berlin-Buch, Berlin, Germany, D-13125; GBG Forschungs GmbH, Germany; NSABP, Pittsburgh, PA; Institut Bergonié, INSERM U916; Jules Bordet Institute, Brussels, Belgium; San Raffaele Scientific Insitute, Milan, Italy; Fondazione Michelangelo, Milan, Italy; Cancer Therapy Evaluation Program, NCI, Bethesda, MD; Medstar Washington Hospital Center, Washington, DC; EORTC Headquarters, Brussels, Belgium; Memorial Sloan-Kettering Cancer Center, New York; Orlando Health MD Anderson Cancer Center
| | - TM Prowell
- FDA; HELIOS Klinikum Berlin-Buch, Berlin, Germany, D-13125; GBG Forschungs GmbH, Germany; NSABP, Pittsburgh, PA; Institut Bergonié, INSERM U916; Jules Bordet Institute, Brussels, Belgium; San Raffaele Scientific Insitute, Milan, Italy; Fondazione Michelangelo, Milan, Italy; Cancer Therapy Evaluation Program, NCI, Bethesda, MD; Medstar Washington Hospital Center, Washington, DC; EORTC Headquarters, Brussels, Belgium; Memorial Sloan-Kettering Cancer Center, New York; Orlando Health MD Anderson Cancer Center
| | - P Rastogi
- FDA; HELIOS Klinikum Berlin-Buch, Berlin, Germany, D-13125; GBG Forschungs GmbH, Germany; NSABP, Pittsburgh, PA; Institut Bergonié, INSERM U916; Jules Bordet Institute, Brussels, Belgium; San Raffaele Scientific Insitute, Milan, Italy; Fondazione Michelangelo, Milan, Italy; Cancer Therapy Evaluation Program, NCI, Bethesda, MD; Medstar Washington Hospital Center, Washington, DC; EORTC Headquarters, Brussels, Belgium; Memorial Sloan-Kettering Cancer Center, New York; Orlando Health MD Anderson Cancer Center
| | - R Sridhara
- FDA; HELIOS Klinikum Berlin-Buch, Berlin, Germany, D-13125; GBG Forschungs GmbH, Germany; NSABP, Pittsburgh, PA; Institut Bergonié, INSERM U916; Jules Bordet Institute, Brussels, Belgium; San Raffaele Scientific Insitute, Milan, Italy; Fondazione Michelangelo, Milan, Italy; Cancer Therapy Evaluation Program, NCI, Bethesda, MD; Medstar Washington Hospital Center, Washington, DC; EORTC Headquarters, Brussels, Belgium; Memorial Sloan-Kettering Cancer Center, New York; Orlando Health MD Anderson Cancer Center
| | - S Tang
- FDA; HELIOS Klinikum Berlin-Buch, Berlin, Germany, D-13125; GBG Forschungs GmbH, Germany; NSABP, Pittsburgh, PA; Institut Bergonié, INSERM U916; Jules Bordet Institute, Brussels, Belgium; San Raffaele Scientific Insitute, Milan, Italy; Fondazione Michelangelo, Milan, Italy; Cancer Therapy Evaluation Program, NCI, Bethesda, MD; Medstar Washington Hospital Center, Washington, DC; EORTC Headquarters, Brussels, Belgium; Memorial Sloan-Kettering Cancer Center, New York; Orlando Health MD Anderson Cancer Center
| | - R Pazdur
- FDA; HELIOS Klinikum Berlin-Buch, Berlin, Germany, D-13125; GBG Forschungs GmbH, Germany; NSABP, Pittsburgh, PA; Institut Bergonié, INSERM U916; Jules Bordet Institute, Brussels, Belgium; San Raffaele Scientific Insitute, Milan, Italy; Fondazione Michelangelo, Milan, Italy; Cancer Therapy Evaluation Program, NCI, Bethesda, MD; Medstar Washington Hospital Center, Washington, DC; EORTC Headquarters, Brussels, Belgium; Memorial Sloan-Kettering Cancer Center, New York; Orlando Health MD Anderson Cancer Center
| | - E Mamounas
- FDA; HELIOS Klinikum Berlin-Buch, Berlin, Germany, D-13125; GBG Forschungs GmbH, Germany; NSABP, Pittsburgh, PA; Institut Bergonié, INSERM U916; Jules Bordet Institute, Brussels, Belgium; San Raffaele Scientific Insitute, Milan, Italy; Fondazione Michelangelo, Milan, Italy; Cancer Therapy Evaluation Program, NCI, Bethesda, MD; Medstar Washington Hospital Center, Washington, DC; EORTC Headquarters, Brussels, Belgium; Memorial Sloan-Kettering Cancer Center, New York; Orlando Health MD Anderson Cancer Center
| | - G von Minckwitz
- FDA; HELIOS Klinikum Berlin-Buch, Berlin, Germany, D-13125; GBG Forschungs GmbH, Germany; NSABP, Pittsburgh, PA; Institut Bergonié, INSERM U916; Jules Bordet Institute, Brussels, Belgium; San Raffaele Scientific Insitute, Milan, Italy; Fondazione Michelangelo, Milan, Italy; Cancer Therapy Evaluation Program, NCI, Bethesda, MD; Medstar Washington Hospital Center, Washington, DC; EORTC Headquarters, Brussels, Belgium; Memorial Sloan-Kettering Cancer Center, New York; Orlando Health MD Anderson Cancer Center
| |
Collapse
|
37
|
von Minckwitz G, Rezai M, Eidtmann H, Tesch H, Huober J, Gerber B, Zahn DM, Costa S, Gnant M, Blohmer JU, Denkert C, Hanusch C, Jackisch C, Kümmel S, Fasching PA, Schneeweiss A, Paepke S, Untch M, Nekljudova V, Mehta K, Loibl S. Abstract S5-05: Postneoadjuvant treatment with zoledronate in patients with tumor residuals after anthracyclines-taxane-based chemotherapy for primary breast cancer – The phase III NATAN study (GBG 36/ABCSG XX). Cancer Res 2013. [DOI: 10.1158/0008-5472.sabcs13-s5-05] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Background: Patients with residual disease after neoadjuvant chemotherapy (NACT) are considered to have chemoresistant breast cancer. Adjuvant treatment with bisphosphonates is considered to reduce the relapse risk predominantly in estrogen-deprivated patients.
Methods: Patients who had invasive tumor residuals (ypT1-4 or ypN+) after a minimum of 4 cycles of anthracycline-taxane-containing NACT were eligible to the NATAN study. Patients were randomized within 3 years after surgery to receive zoledronate 4 mg i.v. (plus 1000 mg Ca2+ and 880 I.U. vitamin D daily) for 5 years vs. observation. Zoledronate was given q 4 weeks for the first 6 months, q 3 months the following 2 years, and q 6 months for the last 2.5 years. Patients with hormone receptor (HR)-positive disease received letrozole for 5 years if postmenopausal, or tamoxifen, if premenopausal. Adjuvant trastuzumab for HER2-positive disease was allowed since an amendment in 2007. Stratification factors were HR, time since surgery, age, and center. Primary objective was event-free survival (EFS). 654 patients and 316 events were required to observe an increase of 5yr EFS from 58% to 67.2% (hazard ratio 0.73). Secondary objectives were to determine overall survival, EFS with respect to the interval between surgery and randomization, bone-metastasis-free-survival, toxicity of and compliance to zoledronate, the predictive value of breast tumor response to NACT on the effect of postoperative treatment and the prognostic impact of chemotherapy induced amenorrhea in premenopausal patients. An interim analysis for high efficacy at 158 observed events was planned in the protocol; in agreement with study IDMC a Bayesian analysis for futility with futility boundary of 15% will be performed at the same time.
Results: Between 2/2005 and 5/2009 693 patients were enrolled. Time between surgery and randomization was <4 months in 48.4%, 4-12 months in 34.5%, and 13-36 months in 17.1% of patients. The median age was 50.9 yrs (range 33.7-88.2), 72.3% of patients were postmenopausal. 82% had HR-positive and 19% HER2-positive disease. During a median follow up of 48 months 154 events were observed so far.
Conclusion: This is the first post-neoadjuvant phase III study. Analysis of the primary endpoint will be presented in case the IDMC will release of the results of the futility analysis.
Citation Information: Cancer Res 2013;73(24 Suppl): Abstract nr S5-05.
Collapse
Affiliation(s)
- G von Minckwitz
- German Breast Group, Neu-Isenburg, Germany; Luisenkrankenhaus Düsseldorf, Germany; Universitäts Frauenklinik Kiel, Germany; Onkologische Gemeinschaftspraxis, Frankfurt, Germany; Frauenklinik Ulm, Germany; Universitäts-Frauenklinik Rostock, Germany; SRH Wald Klinikum Gera, Germany; Universitätsklinikum Magdeburg, Germany; Medical University of Vienna, Austria; Sankt Gertrauden Krankenhaus, Berlin, Germany; Charité University, Berlin, Germany; Rotkruezklinikum München, Germany; Klinikum Offenbach, Germany; Kliniken Essen Mitte, Germany; University Erlangen, Germany; University Heidelberg; Klinikum Rechts der Isar der TU München, Germany; Helios Kliniken Berlin, Germany; Frauenklinik Frankfurt, Germany
| | - M Rezai
- German Breast Group, Neu-Isenburg, Germany; Luisenkrankenhaus Düsseldorf, Germany; Universitäts Frauenklinik Kiel, Germany; Onkologische Gemeinschaftspraxis, Frankfurt, Germany; Frauenklinik Ulm, Germany; Universitäts-Frauenklinik Rostock, Germany; SRH Wald Klinikum Gera, Germany; Universitätsklinikum Magdeburg, Germany; Medical University of Vienna, Austria; Sankt Gertrauden Krankenhaus, Berlin, Germany; Charité University, Berlin, Germany; Rotkruezklinikum München, Germany; Klinikum Offenbach, Germany; Kliniken Essen Mitte, Germany; University Erlangen, Germany; University Heidelberg; Klinikum Rechts der Isar der TU München, Germany; Helios Kliniken Berlin, Germany; Frauenklinik Frankfurt, Germany
| | - H Eidtmann
- German Breast Group, Neu-Isenburg, Germany; Luisenkrankenhaus Düsseldorf, Germany; Universitäts Frauenklinik Kiel, Germany; Onkologische Gemeinschaftspraxis, Frankfurt, Germany; Frauenklinik Ulm, Germany; Universitäts-Frauenklinik Rostock, Germany; SRH Wald Klinikum Gera, Germany; Universitätsklinikum Magdeburg, Germany; Medical University of Vienna, Austria; Sankt Gertrauden Krankenhaus, Berlin, Germany; Charité University, Berlin, Germany; Rotkruezklinikum München, Germany; Klinikum Offenbach, Germany; Kliniken Essen Mitte, Germany; University Erlangen, Germany; University Heidelberg; Klinikum Rechts der Isar der TU München, Germany; Helios Kliniken Berlin, Germany; Frauenklinik Frankfurt, Germany
| | - H Tesch
- German Breast Group, Neu-Isenburg, Germany; Luisenkrankenhaus Düsseldorf, Germany; Universitäts Frauenklinik Kiel, Germany; Onkologische Gemeinschaftspraxis, Frankfurt, Germany; Frauenklinik Ulm, Germany; Universitäts-Frauenklinik Rostock, Germany; SRH Wald Klinikum Gera, Germany; Universitätsklinikum Magdeburg, Germany; Medical University of Vienna, Austria; Sankt Gertrauden Krankenhaus, Berlin, Germany; Charité University, Berlin, Germany; Rotkruezklinikum München, Germany; Klinikum Offenbach, Germany; Kliniken Essen Mitte, Germany; University Erlangen, Germany; University Heidelberg; Klinikum Rechts der Isar der TU München, Germany; Helios Kliniken Berlin, Germany; Frauenklinik Frankfurt, Germany
| | - J Huober
- German Breast Group, Neu-Isenburg, Germany; Luisenkrankenhaus Düsseldorf, Germany; Universitäts Frauenklinik Kiel, Germany; Onkologische Gemeinschaftspraxis, Frankfurt, Germany; Frauenklinik Ulm, Germany; Universitäts-Frauenklinik Rostock, Germany; SRH Wald Klinikum Gera, Germany; Universitätsklinikum Magdeburg, Germany; Medical University of Vienna, Austria; Sankt Gertrauden Krankenhaus, Berlin, Germany; Charité University, Berlin, Germany; Rotkruezklinikum München, Germany; Klinikum Offenbach, Germany; Kliniken Essen Mitte, Germany; University Erlangen, Germany; University Heidelberg; Klinikum Rechts der Isar der TU München, Germany; Helios Kliniken Berlin, Germany; Frauenklinik Frankfurt, Germany
| | - B Gerber
- German Breast Group, Neu-Isenburg, Germany; Luisenkrankenhaus Düsseldorf, Germany; Universitäts Frauenklinik Kiel, Germany; Onkologische Gemeinschaftspraxis, Frankfurt, Germany; Frauenklinik Ulm, Germany; Universitäts-Frauenklinik Rostock, Germany; SRH Wald Klinikum Gera, Germany; Universitätsklinikum Magdeburg, Germany; Medical University of Vienna, Austria; Sankt Gertrauden Krankenhaus, Berlin, Germany; Charité University, Berlin, Germany; Rotkruezklinikum München, Germany; Klinikum Offenbach, Germany; Kliniken Essen Mitte, Germany; University Erlangen, Germany; University Heidelberg; Klinikum Rechts der Isar der TU München, Germany; Helios Kliniken Berlin, Germany; Frauenklinik Frankfurt, Germany
| | - DM Zahn
- German Breast Group, Neu-Isenburg, Germany; Luisenkrankenhaus Düsseldorf, Germany; Universitäts Frauenklinik Kiel, Germany; Onkologische Gemeinschaftspraxis, Frankfurt, Germany; Frauenklinik Ulm, Germany; Universitäts-Frauenklinik Rostock, Germany; SRH Wald Klinikum Gera, Germany; Universitätsklinikum Magdeburg, Germany; Medical University of Vienna, Austria; Sankt Gertrauden Krankenhaus, Berlin, Germany; Charité University, Berlin, Germany; Rotkruezklinikum München, Germany; Klinikum Offenbach, Germany; Kliniken Essen Mitte, Germany; University Erlangen, Germany; University Heidelberg; Klinikum Rechts der Isar der TU München, Germany; Helios Kliniken Berlin, Germany; Frauenklinik Frankfurt, Germany
| | - S Costa
- German Breast Group, Neu-Isenburg, Germany; Luisenkrankenhaus Düsseldorf, Germany; Universitäts Frauenklinik Kiel, Germany; Onkologische Gemeinschaftspraxis, Frankfurt, Germany; Frauenklinik Ulm, Germany; Universitäts-Frauenklinik Rostock, Germany; SRH Wald Klinikum Gera, Germany; Universitätsklinikum Magdeburg, Germany; Medical University of Vienna, Austria; Sankt Gertrauden Krankenhaus, Berlin, Germany; Charité University, Berlin, Germany; Rotkruezklinikum München, Germany; Klinikum Offenbach, Germany; Kliniken Essen Mitte, Germany; University Erlangen, Germany; University Heidelberg; Klinikum Rechts der Isar der TU München, Germany; Helios Kliniken Berlin, Germany; Frauenklinik Frankfurt, Germany
| | - M Gnant
- German Breast Group, Neu-Isenburg, Germany; Luisenkrankenhaus Düsseldorf, Germany; Universitäts Frauenklinik Kiel, Germany; Onkologische Gemeinschaftspraxis, Frankfurt, Germany; Frauenklinik Ulm, Germany; Universitäts-Frauenklinik Rostock, Germany; SRH Wald Klinikum Gera, Germany; Universitätsklinikum Magdeburg, Germany; Medical University of Vienna, Austria; Sankt Gertrauden Krankenhaus, Berlin, Germany; Charité University, Berlin, Germany; Rotkruezklinikum München, Germany; Klinikum Offenbach, Germany; Kliniken Essen Mitte, Germany; University Erlangen, Germany; University Heidelberg; Klinikum Rechts der Isar der TU München, Germany; Helios Kliniken Berlin, Germany; Frauenklinik Frankfurt, Germany
| | - JU Blohmer
- German Breast Group, Neu-Isenburg, Germany; Luisenkrankenhaus Düsseldorf, Germany; Universitäts Frauenklinik Kiel, Germany; Onkologische Gemeinschaftspraxis, Frankfurt, Germany; Frauenklinik Ulm, Germany; Universitäts-Frauenklinik Rostock, Germany; SRH Wald Klinikum Gera, Germany; Universitätsklinikum Magdeburg, Germany; Medical University of Vienna, Austria; Sankt Gertrauden Krankenhaus, Berlin, Germany; Charité University, Berlin, Germany; Rotkruezklinikum München, Germany; Klinikum Offenbach, Germany; Kliniken Essen Mitte, Germany; University Erlangen, Germany; University Heidelberg; Klinikum Rechts der Isar der TU München, Germany; Helios Kliniken Berlin, Germany; Frauenklinik Frankfurt, Germany
| | - C Denkert
- German Breast Group, Neu-Isenburg, Germany; Luisenkrankenhaus Düsseldorf, Germany; Universitäts Frauenklinik Kiel, Germany; Onkologische Gemeinschaftspraxis, Frankfurt, Germany; Frauenklinik Ulm, Germany; Universitäts-Frauenklinik Rostock, Germany; SRH Wald Klinikum Gera, Germany; Universitätsklinikum Magdeburg, Germany; Medical University of Vienna, Austria; Sankt Gertrauden Krankenhaus, Berlin, Germany; Charité University, Berlin, Germany; Rotkruezklinikum München, Germany; Klinikum Offenbach, Germany; Kliniken Essen Mitte, Germany; University Erlangen, Germany; University Heidelberg; Klinikum Rechts der Isar der TU München, Germany; Helios Kliniken Berlin, Germany; Frauenklinik Frankfurt, Germany
| | - C Hanusch
- German Breast Group, Neu-Isenburg, Germany; Luisenkrankenhaus Düsseldorf, Germany; Universitäts Frauenklinik Kiel, Germany; Onkologische Gemeinschaftspraxis, Frankfurt, Germany; Frauenklinik Ulm, Germany; Universitäts-Frauenklinik Rostock, Germany; SRH Wald Klinikum Gera, Germany; Universitätsklinikum Magdeburg, Germany; Medical University of Vienna, Austria; Sankt Gertrauden Krankenhaus, Berlin, Germany; Charité University, Berlin, Germany; Rotkruezklinikum München, Germany; Klinikum Offenbach, Germany; Kliniken Essen Mitte, Germany; University Erlangen, Germany; University Heidelberg; Klinikum Rechts der Isar der TU München, Germany; Helios Kliniken Berlin, Germany; Frauenklinik Frankfurt, Germany
| | - C Jackisch
- German Breast Group, Neu-Isenburg, Germany; Luisenkrankenhaus Düsseldorf, Germany; Universitäts Frauenklinik Kiel, Germany; Onkologische Gemeinschaftspraxis, Frankfurt, Germany; Frauenklinik Ulm, Germany; Universitäts-Frauenklinik Rostock, Germany; SRH Wald Klinikum Gera, Germany; Universitätsklinikum Magdeburg, Germany; Medical University of Vienna, Austria; Sankt Gertrauden Krankenhaus, Berlin, Germany; Charité University, Berlin, Germany; Rotkruezklinikum München, Germany; Klinikum Offenbach, Germany; Kliniken Essen Mitte, Germany; University Erlangen, Germany; University Heidelberg; Klinikum Rechts der Isar der TU München, Germany; Helios Kliniken Berlin, Germany; Frauenklinik Frankfurt, Germany
| | - S Kümmel
- German Breast Group, Neu-Isenburg, Germany; Luisenkrankenhaus Düsseldorf, Germany; Universitäts Frauenklinik Kiel, Germany; Onkologische Gemeinschaftspraxis, Frankfurt, Germany; Frauenklinik Ulm, Germany; Universitäts-Frauenklinik Rostock, Germany; SRH Wald Klinikum Gera, Germany; Universitätsklinikum Magdeburg, Germany; Medical University of Vienna, Austria; Sankt Gertrauden Krankenhaus, Berlin, Germany; Charité University, Berlin, Germany; Rotkruezklinikum München, Germany; Klinikum Offenbach, Germany; Kliniken Essen Mitte, Germany; University Erlangen, Germany; University Heidelberg; Klinikum Rechts der Isar der TU München, Germany; Helios Kliniken Berlin, Germany; Frauenklinik Frankfurt, Germany
| | - PA Fasching
- German Breast Group, Neu-Isenburg, Germany; Luisenkrankenhaus Düsseldorf, Germany; Universitäts Frauenklinik Kiel, Germany; Onkologische Gemeinschaftspraxis, Frankfurt, Germany; Frauenklinik Ulm, Germany; Universitäts-Frauenklinik Rostock, Germany; SRH Wald Klinikum Gera, Germany; Universitätsklinikum Magdeburg, Germany; Medical University of Vienna, Austria; Sankt Gertrauden Krankenhaus, Berlin, Germany; Charité University, Berlin, Germany; Rotkruezklinikum München, Germany; Klinikum Offenbach, Germany; Kliniken Essen Mitte, Germany; University Erlangen, Germany; University Heidelberg; Klinikum Rechts der Isar der TU München, Germany; Helios Kliniken Berlin, Germany; Frauenklinik Frankfurt, Germany
| | - A Schneeweiss
- German Breast Group, Neu-Isenburg, Germany; Luisenkrankenhaus Düsseldorf, Germany; Universitäts Frauenklinik Kiel, Germany; Onkologische Gemeinschaftspraxis, Frankfurt, Germany; Frauenklinik Ulm, Germany; Universitäts-Frauenklinik Rostock, Germany; SRH Wald Klinikum Gera, Germany; Universitätsklinikum Magdeburg, Germany; Medical University of Vienna, Austria; Sankt Gertrauden Krankenhaus, Berlin, Germany; Charité University, Berlin, Germany; Rotkruezklinikum München, Germany; Klinikum Offenbach, Germany; Kliniken Essen Mitte, Germany; University Erlangen, Germany; University Heidelberg; Klinikum Rechts der Isar der TU München, Germany; Helios Kliniken Berlin, Germany; Frauenklinik Frankfurt, Germany
| | - S Paepke
- German Breast Group, Neu-Isenburg, Germany; Luisenkrankenhaus Düsseldorf, Germany; Universitäts Frauenklinik Kiel, Germany; Onkologische Gemeinschaftspraxis, Frankfurt, Germany; Frauenklinik Ulm, Germany; Universitäts-Frauenklinik Rostock, Germany; SRH Wald Klinikum Gera, Germany; Universitätsklinikum Magdeburg, Germany; Medical University of Vienna, Austria; Sankt Gertrauden Krankenhaus, Berlin, Germany; Charité University, Berlin, Germany; Rotkruezklinikum München, Germany; Klinikum Offenbach, Germany; Kliniken Essen Mitte, Germany; University Erlangen, Germany; University Heidelberg; Klinikum Rechts der Isar der TU München, Germany; Helios Kliniken Berlin, Germany; Frauenklinik Frankfurt, Germany
| | - M Untch
- German Breast Group, Neu-Isenburg, Germany; Luisenkrankenhaus Düsseldorf, Germany; Universitäts Frauenklinik Kiel, Germany; Onkologische Gemeinschaftspraxis, Frankfurt, Germany; Frauenklinik Ulm, Germany; Universitäts-Frauenklinik Rostock, Germany; SRH Wald Klinikum Gera, Germany; Universitätsklinikum Magdeburg, Germany; Medical University of Vienna, Austria; Sankt Gertrauden Krankenhaus, Berlin, Germany; Charité University, Berlin, Germany; Rotkruezklinikum München, Germany; Klinikum Offenbach, Germany; Kliniken Essen Mitte, Germany; University Erlangen, Germany; University Heidelberg; Klinikum Rechts der Isar der TU München, Germany; Helios Kliniken Berlin, Germany; Frauenklinik Frankfurt, Germany
| | - V Nekljudova
- German Breast Group, Neu-Isenburg, Germany; Luisenkrankenhaus Düsseldorf, Germany; Universitäts Frauenklinik Kiel, Germany; Onkologische Gemeinschaftspraxis, Frankfurt, Germany; Frauenklinik Ulm, Germany; Universitäts-Frauenklinik Rostock, Germany; SRH Wald Klinikum Gera, Germany; Universitätsklinikum Magdeburg, Germany; Medical University of Vienna, Austria; Sankt Gertrauden Krankenhaus, Berlin, Germany; Charité University, Berlin, Germany; Rotkruezklinikum München, Germany; Klinikum Offenbach, Germany; Kliniken Essen Mitte, Germany; University Erlangen, Germany; University Heidelberg; Klinikum Rechts der Isar der TU München, Germany; Helios Kliniken Berlin, Germany; Frauenklinik Frankfurt, Germany
| | - K Mehta
- German Breast Group, Neu-Isenburg, Germany; Luisenkrankenhaus Düsseldorf, Germany; Universitäts Frauenklinik Kiel, Germany; Onkologische Gemeinschaftspraxis, Frankfurt, Germany; Frauenklinik Ulm, Germany; Universitäts-Frauenklinik Rostock, Germany; SRH Wald Klinikum Gera, Germany; Universitätsklinikum Magdeburg, Germany; Medical University of Vienna, Austria; Sankt Gertrauden Krankenhaus, Berlin, Germany; Charité University, Berlin, Germany; Rotkruezklinikum München, Germany; Klinikum Offenbach, Germany; Kliniken Essen Mitte, Germany; University Erlangen, Germany; University Heidelberg; Klinikum Rechts der Isar der TU München, Germany; Helios Kliniken Berlin, Germany; Frauenklinik Frankfurt, Germany
| | - S Loibl
- German Breast Group, Neu-Isenburg, Germany; Luisenkrankenhaus Düsseldorf, Germany; Universitäts Frauenklinik Kiel, Germany; Onkologische Gemeinschaftspraxis, Frankfurt, Germany; Frauenklinik Ulm, Germany; Universitäts-Frauenklinik Rostock, Germany; SRH Wald Klinikum Gera, Germany; Universitätsklinikum Magdeburg, Germany; Medical University of Vienna, Austria; Sankt Gertrauden Krankenhaus, Berlin, Germany; Charité University, Berlin, Germany; Rotkruezklinikum München, Germany; Klinikum Offenbach, Germany; Kliniken Essen Mitte, Germany; University Erlangen, Germany; University Heidelberg; Klinikum Rechts der Isar der TU München, Germany; Helios Kliniken Berlin, Germany; Frauenklinik Frankfurt, Germany
| |
Collapse
|
38
|
von Minckwitz G, Rezai M, Fasching PA, Huober J, Tesch H, Bauerfeind I, Hilfrich J, Eidtmann H, Gerber B, Hanusch C, Blohmer JU, Costa SD, Jackisch C, Paepke S, Schneeweiss A, Kümmel S, Denkert C, Mehta K, Loibl S, Untch M. Survival after adding capecitabine and trastuzumab to neoadjuvant anthracycline-taxane-based chemotherapy for primary breast cancer (GBG 40--GeparQuattro). Ann Oncol 2013; 25:81-9. [PMID: 24273046 DOI: 10.1093/annonc/mdt410] [Citation(s) in RCA: 46] [Impact Index Per Article: 4.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/19/2023] Open
Abstract
BACKGROUND The GeparQuattro study showed that adding capecitabine or prolonging the duration of anthracycline-taxane-based neoadjuvant chemotherapy from 24 to 36 weeks did not increase pathological complete response (pCR) rates. Trastuzumab-treated patients with HER2-positive disease showed a higher pCR rate than patients with HER2-negative disease treated with chemotherapy alone. We here present disease-free (DFS) and overall survival (OS) analyses. PATIENTS AND METHODS Patients (n = 1495) with cT ≥ 3 tumors, or negative hormone-receptor status, or positive hormone-receptor and clinically node-positive disease received four times epirubicin/cyclophosphamide and were thereafter randomly assigned to four times docetaxel (Taxotere), or four times docetaxel/capecitabine over 24 weeks, or four times docetaxel followed by capecitabine over 36 weeks. Patients with HER2-positive tumors received 1 year of trastuzumab, starting with the first chemotherapy cycle. Follow-up was available for a median of 5.4 years. RESULTS Outcome was not improved for patients receiving capecitabine (HR 0.92; P = 0.463 for DFS and HR 93; P = 0.618 for OS) as well as for patients receiving 36 weeks of chemotherapy (HR 0.97; P = 0.818 for DFS and HR 0.97; P = 0.825 for OS). Trastuzumab-treated patients with HER2-positive disease showed similar DFS (P = 0.305) but a significantly better adjusted OS (P = 0.040) when compared with patients with HER2-negative disease treated with chemotherapy alone. Recorded long-term cardiac toxicity was low. CONCLUSIONS Long-term results, similar to the results of pCR, do not support the use of capecitabine in the neoadjuvant setting in addition to an anthracycline-taxane-based chemotherapy. However, the results support previous data showing a benefit of trastuzumab as predicted by higher pCR rates.
Collapse
|
39
|
Baliga S, Mehta K, Goldberg G, Kalnicki S. Stereotactic Body Radiation Therapy in Oligo-Metastatic Recurrent Ovarian Cancer. Int J Radiat Oncol Biol Phys 2013. [DOI: 10.1016/j.ijrobp.2013.06.1119] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/26/2022]
|
40
|
Pahlajani D, Kaul U, Mishra A, Mullasari A, Sawhney J, Dargad R, Mehta K, Sinha N. Prospective pre-test and clinical scoring in subjects with suspected coronary disease estimates the probability of coronary artery disease: the Prospective Stable Angina Observational registry, India. Eur Heart J 2013. [DOI: 10.1093/eurheartj/eht309.p3143] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
41
|
Sinn BV, von Minckwitz G, Denkert C, Eidtmann H, Darb-Esfahani S, Tesch H, Kronenwett R, Hoffmann G, Belau A, Thommsen C, Holzhausen HJ, Grasshoff ST, Baumann K, Mehta K, Dietel M, Loibl S. Evaluation of Mucin-1 protein and mRNA expression as prognostic and predictive markers after neoadjuvant chemotherapy for breast cancer. Ann Oncol 2013; 24:2316-24. [PMID: 23661292 DOI: 10.1093/annonc/mdt162] [Citation(s) in RCA: 27] [Impact Index Per Article: 2.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/03/2023] Open
Abstract
BACKGROUND Mucin-1 (MUC1) is a promising antigen for the development of tumor vaccines. We evaluated the frequency of MUC1 expression and its impact on therapy response and survival after neoadjuvant chemotherapy for breast cancer. PATIENTS AND METHODS Pre-treatment core biopsies of patients from the GeparTrio neoadjuvant trial (NCT 00544765) were evaluated for MUC1 by immunohistochemistry (IHC; N = 691) and quantitative RT-PCR (qRT-PCR; N = 286) from formalin-fixed paraffin-embedded (FFPE) samples. RESULTS MUC1 protein and mRNA was detectable in the majority of cases and was associated with hormone-receptor-positive status (P < 0.001). High MUC1 protein and mRNA expression were associated with lower probability of pathologic complete response (P = 0.017 and P < 0.001) and with longer patient survival (P = 0.03 and P < 0.001). In multivariable analysis, MUC1 protein and mRNA expression were independently predictive (P = 0.001 and P < 0.001). MUC1 protein and mRNA expression were independently prognostic for overall survival (P = 0.029 and P = 0.015). CONCLUSIONS MUC1 is frequently expressed in breast cancer and detectable on mRNA and protein level from FFPE tissue. It provides independent predictive information for therapy response and survival after neoadjuvant chemotherapy. In clinical immunotherapy trials, MUC1 expression may serve as a predictive marker.
Collapse
Affiliation(s)
- B V Sinn
- Department of Pathology, Charité-Universitätsmedizin Berlin, Berlin.
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
42
|
Mansor L, Mehta K, L Page L, Carr C, Clarke K, Heather L. 234 IMPAIRED METABOLIC AND FUNCTIONAL ADAPTATION TO HYPOXIA IN THE TYPE 2 DIABETIC HEART. Heart 2013. [DOI: 10.1136/heartjnl-2013-304019.234] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 11/03/2022]
|
43
|
Bernstein M, Yaparpalvi R, Kuo H, Kalnicki S, Mehta K. CT-Guidance Allows Interstitial Implantation in an Outpatient Setting for Cervical Cancer Patients. Pract Radiat Oncol 2013; 3:S1. [PMID: 24674470 DOI: 10.1016/j.prro.2013.01.007] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/17/2022]
Affiliation(s)
| | | | - H Kuo
- Montefiore Medical Center, Bronx, NY
| | | | - K Mehta
- Montefiore Medical Center, Bronx, NY
| |
Collapse
|
44
|
Glanzman J, Weiss P, Mehta K, Bodner W, Kalnicki S, Garg M. PO-0986: Surgical resection followed by HDR brachytherapy for management of keloids at high risk for recurrence. Radiother Oncol 2013. [DOI: 10.1016/s0167-8140(15)33292-8] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
|
45
|
von Minckwitz G, Rezai M, Loibl S, Fasching PA, Huober J, Tesch H, Bauerfeind I, Hilfrich J, Eidtmann H, Gerber B, Hanusch C, Blohmer JU, Costa SD, Jackisch C, Paepke S, Schneeweiss A, Kuemmel S, Denkert C, Mehta K, Untch M. Abstract P1-14-01: Adding capecitabine and trastuzumab to neoadjuvant breast cancer chemotherapy - first survival analysis of the GBG/AGO intergroup-study GeparQuattro. Cancer Res 2012. [DOI: 10.1158/0008-5472.sabcs12-p1-14-01] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Background: Previous results of the GeparQuattro study demonstrated that adding capecitabine either simultaneously or sequentially to EC-Docetaxel (D) neoadjuvant chemotherapy could not increase pathological complete response rates (pCR) (von Minckwitz G, JCO 2010). However, patients with HER2-positive disease treated simultaneously with trastuzumab showed a significant higher pCR rate than patients with HER2-negative disease treated with chemotherapy alone (Untch M, JCO 2010). We here report survival after a median follow up of 58 months including 279 relapses and 191 deaths.
Patients and methods: Patients with either large operable (cT3) and locally advanced (cT4) tumors, or hormone-receptor (HR)-negative receptor status, or HR-positive tumors but clinically node-positive disease were recruited to receive 4 cycles of EC (90mg/m2/600mg/m2) and randomized to either 4 cycles of D (100mg/m2) or 4 cycles of DX (75mg/m2/1800mg/m2) or 4 cycles of D (75mg/m2) followed by 4 cycles of X (1800mg/m2) (D→X). Patients with HER-2 positive tumors received 1 year of trastuzumab, the first part concurrent to all chemotherapy cycles. All patients with HR+ tumors received endocrine therapy according to current standard. The intent-to-treat survival analysis included 1421 patients for the chemotherapy question and 1495 patients for the trastuzumab question. Analyses were adjusted by age, stage, size, nodal status, histologic type, grade, hormone-receptor (HR) and HER2-status at baseline (if applicable).
Results: No difference in DFS and OS was seen for patients receiving D, DX or D-X overall (hazard ratio 0.978, p = 0.984 and hazard ratio 0.986, p = 0.684, respectively) as well as by phenotype defined according to St. Gallen (all P>0.354).
Patients with HER2-positive disease treated additionally with trastuzumab showed significantly better OS (p = 0.015) compared to patients with HER2-negative disease treated with chemotherapy alone. DFS was significantly better for trastuzumab-treated patients with HR-negative tumors (p = 0.046), but not with HR-positive tumors (p = 0.790). OS after first relapse was significantly better in trastuzumab-retreated patients with HER2-positive tumors (p = 0.032) compared to relapsed patients with HER2-negative tumors.
Patients with an early response after 4 cycles, with a clinical response at surgery and with a pCR showed a significantly better DFS and OS compared to patients without pCR (p = 0.022, P < 0.0001, P < 0.0001). This benefit was most prominent in patients with triple-negative tumors.
Conclusions: Survival analysis of the GeparQuattro study confirmed the results of the primary endpoint analysis on pCR. Capecitabine could not improve outcome when added to anthracycline-taxane-based chemotherapy. As suggested by a recent integrated multi-level meta-analysis (von Minckwitz, BCRT 2011) effect of capecitabine could not be properly assessed in this study as planned docetaxel doses in arms DX and D®X were lower than in arm D. Survival of HER-2 positive patients surmounts that of HER2-negative patients if trastuzumab is used in the neoadjuvant as well as in the metastatic setting.
Citation Information: Cancer Res 2012;72(24 Suppl):Abstract nr P1-14-01.
Collapse
Affiliation(s)
- G von Minckwitz
- German Breast Group, Neu-Isenburg; Louisenkrankenhaus Düsseldorf; University Erlangen; University Duesseldorf; Bethanien-Kankenhaus Frankfurt; Klinikum Landshut; Eilenriedeklinik Duesseldorf; University Kiel; University Rostock; Roteskreuzklinikum Muenchen; Sankt Gertrauden Berlin; University Magdeburg; Klinikum Offenbach; Frauenklinik München; University Heidelberg; Kliniken Essen Mitte; Charite Berlin; Helios Kliniken Berlin
| | - M Rezai
- German Breast Group, Neu-Isenburg; Louisenkrankenhaus Düsseldorf; University Erlangen; University Duesseldorf; Bethanien-Kankenhaus Frankfurt; Klinikum Landshut; Eilenriedeklinik Duesseldorf; University Kiel; University Rostock; Roteskreuzklinikum Muenchen; Sankt Gertrauden Berlin; University Magdeburg; Klinikum Offenbach; Frauenklinik München; University Heidelberg; Kliniken Essen Mitte; Charite Berlin; Helios Kliniken Berlin
| | - S Loibl
- German Breast Group, Neu-Isenburg; Louisenkrankenhaus Düsseldorf; University Erlangen; University Duesseldorf; Bethanien-Kankenhaus Frankfurt; Klinikum Landshut; Eilenriedeklinik Duesseldorf; University Kiel; University Rostock; Roteskreuzklinikum Muenchen; Sankt Gertrauden Berlin; University Magdeburg; Klinikum Offenbach; Frauenklinik München; University Heidelberg; Kliniken Essen Mitte; Charite Berlin; Helios Kliniken Berlin
| | - PA Fasching
- German Breast Group, Neu-Isenburg; Louisenkrankenhaus Düsseldorf; University Erlangen; University Duesseldorf; Bethanien-Kankenhaus Frankfurt; Klinikum Landshut; Eilenriedeklinik Duesseldorf; University Kiel; University Rostock; Roteskreuzklinikum Muenchen; Sankt Gertrauden Berlin; University Magdeburg; Klinikum Offenbach; Frauenklinik München; University Heidelberg; Kliniken Essen Mitte; Charite Berlin; Helios Kliniken Berlin
| | - J Huober
- German Breast Group, Neu-Isenburg; Louisenkrankenhaus Düsseldorf; University Erlangen; University Duesseldorf; Bethanien-Kankenhaus Frankfurt; Klinikum Landshut; Eilenriedeklinik Duesseldorf; University Kiel; University Rostock; Roteskreuzklinikum Muenchen; Sankt Gertrauden Berlin; University Magdeburg; Klinikum Offenbach; Frauenklinik München; University Heidelberg; Kliniken Essen Mitte; Charite Berlin; Helios Kliniken Berlin
| | - H Tesch
- German Breast Group, Neu-Isenburg; Louisenkrankenhaus Düsseldorf; University Erlangen; University Duesseldorf; Bethanien-Kankenhaus Frankfurt; Klinikum Landshut; Eilenriedeklinik Duesseldorf; University Kiel; University Rostock; Roteskreuzklinikum Muenchen; Sankt Gertrauden Berlin; University Magdeburg; Klinikum Offenbach; Frauenklinik München; University Heidelberg; Kliniken Essen Mitte; Charite Berlin; Helios Kliniken Berlin
| | - I Bauerfeind
- German Breast Group, Neu-Isenburg; Louisenkrankenhaus Düsseldorf; University Erlangen; University Duesseldorf; Bethanien-Kankenhaus Frankfurt; Klinikum Landshut; Eilenriedeklinik Duesseldorf; University Kiel; University Rostock; Roteskreuzklinikum Muenchen; Sankt Gertrauden Berlin; University Magdeburg; Klinikum Offenbach; Frauenklinik München; University Heidelberg; Kliniken Essen Mitte; Charite Berlin; Helios Kliniken Berlin
| | - J Hilfrich
- German Breast Group, Neu-Isenburg; Louisenkrankenhaus Düsseldorf; University Erlangen; University Duesseldorf; Bethanien-Kankenhaus Frankfurt; Klinikum Landshut; Eilenriedeklinik Duesseldorf; University Kiel; University Rostock; Roteskreuzklinikum Muenchen; Sankt Gertrauden Berlin; University Magdeburg; Klinikum Offenbach; Frauenklinik München; University Heidelberg; Kliniken Essen Mitte; Charite Berlin; Helios Kliniken Berlin
| | - H Eidtmann
- German Breast Group, Neu-Isenburg; Louisenkrankenhaus Düsseldorf; University Erlangen; University Duesseldorf; Bethanien-Kankenhaus Frankfurt; Klinikum Landshut; Eilenriedeklinik Duesseldorf; University Kiel; University Rostock; Roteskreuzklinikum Muenchen; Sankt Gertrauden Berlin; University Magdeburg; Klinikum Offenbach; Frauenklinik München; University Heidelberg; Kliniken Essen Mitte; Charite Berlin; Helios Kliniken Berlin
| | - B Gerber
- German Breast Group, Neu-Isenburg; Louisenkrankenhaus Düsseldorf; University Erlangen; University Duesseldorf; Bethanien-Kankenhaus Frankfurt; Klinikum Landshut; Eilenriedeklinik Duesseldorf; University Kiel; University Rostock; Roteskreuzklinikum Muenchen; Sankt Gertrauden Berlin; University Magdeburg; Klinikum Offenbach; Frauenklinik München; University Heidelberg; Kliniken Essen Mitte; Charite Berlin; Helios Kliniken Berlin
| | - C Hanusch
- German Breast Group, Neu-Isenburg; Louisenkrankenhaus Düsseldorf; University Erlangen; University Duesseldorf; Bethanien-Kankenhaus Frankfurt; Klinikum Landshut; Eilenriedeklinik Duesseldorf; University Kiel; University Rostock; Roteskreuzklinikum Muenchen; Sankt Gertrauden Berlin; University Magdeburg; Klinikum Offenbach; Frauenklinik München; University Heidelberg; Kliniken Essen Mitte; Charite Berlin; Helios Kliniken Berlin
| | - J-U Blohmer
- German Breast Group, Neu-Isenburg; Louisenkrankenhaus Düsseldorf; University Erlangen; University Duesseldorf; Bethanien-Kankenhaus Frankfurt; Klinikum Landshut; Eilenriedeklinik Duesseldorf; University Kiel; University Rostock; Roteskreuzklinikum Muenchen; Sankt Gertrauden Berlin; University Magdeburg; Klinikum Offenbach; Frauenklinik München; University Heidelberg; Kliniken Essen Mitte; Charite Berlin; Helios Kliniken Berlin
| | - S-D Costa
- German Breast Group, Neu-Isenburg; Louisenkrankenhaus Düsseldorf; University Erlangen; University Duesseldorf; Bethanien-Kankenhaus Frankfurt; Klinikum Landshut; Eilenriedeklinik Duesseldorf; University Kiel; University Rostock; Roteskreuzklinikum Muenchen; Sankt Gertrauden Berlin; University Magdeburg; Klinikum Offenbach; Frauenklinik München; University Heidelberg; Kliniken Essen Mitte; Charite Berlin; Helios Kliniken Berlin
| | - C Jackisch
- German Breast Group, Neu-Isenburg; Louisenkrankenhaus Düsseldorf; University Erlangen; University Duesseldorf; Bethanien-Kankenhaus Frankfurt; Klinikum Landshut; Eilenriedeklinik Duesseldorf; University Kiel; University Rostock; Roteskreuzklinikum Muenchen; Sankt Gertrauden Berlin; University Magdeburg; Klinikum Offenbach; Frauenklinik München; University Heidelberg; Kliniken Essen Mitte; Charite Berlin; Helios Kliniken Berlin
| | - S Paepke
- German Breast Group, Neu-Isenburg; Louisenkrankenhaus Düsseldorf; University Erlangen; University Duesseldorf; Bethanien-Kankenhaus Frankfurt; Klinikum Landshut; Eilenriedeklinik Duesseldorf; University Kiel; University Rostock; Roteskreuzklinikum Muenchen; Sankt Gertrauden Berlin; University Magdeburg; Klinikum Offenbach; Frauenklinik München; University Heidelberg; Kliniken Essen Mitte; Charite Berlin; Helios Kliniken Berlin
| | - A Schneeweiss
- German Breast Group, Neu-Isenburg; Louisenkrankenhaus Düsseldorf; University Erlangen; University Duesseldorf; Bethanien-Kankenhaus Frankfurt; Klinikum Landshut; Eilenriedeklinik Duesseldorf; University Kiel; University Rostock; Roteskreuzklinikum Muenchen; Sankt Gertrauden Berlin; University Magdeburg; Klinikum Offenbach; Frauenklinik München; University Heidelberg; Kliniken Essen Mitte; Charite Berlin; Helios Kliniken Berlin
| | - S Kuemmel
- German Breast Group, Neu-Isenburg; Louisenkrankenhaus Düsseldorf; University Erlangen; University Duesseldorf; Bethanien-Kankenhaus Frankfurt; Klinikum Landshut; Eilenriedeklinik Duesseldorf; University Kiel; University Rostock; Roteskreuzklinikum Muenchen; Sankt Gertrauden Berlin; University Magdeburg; Klinikum Offenbach; Frauenklinik München; University Heidelberg; Kliniken Essen Mitte; Charite Berlin; Helios Kliniken Berlin
| | - C Denkert
- German Breast Group, Neu-Isenburg; Louisenkrankenhaus Düsseldorf; University Erlangen; University Duesseldorf; Bethanien-Kankenhaus Frankfurt; Klinikum Landshut; Eilenriedeklinik Duesseldorf; University Kiel; University Rostock; Roteskreuzklinikum Muenchen; Sankt Gertrauden Berlin; University Magdeburg; Klinikum Offenbach; Frauenklinik München; University Heidelberg; Kliniken Essen Mitte; Charite Berlin; Helios Kliniken Berlin
| | - K Mehta
- German Breast Group, Neu-Isenburg; Louisenkrankenhaus Düsseldorf; University Erlangen; University Duesseldorf; Bethanien-Kankenhaus Frankfurt; Klinikum Landshut; Eilenriedeklinik Duesseldorf; University Kiel; University Rostock; Roteskreuzklinikum Muenchen; Sankt Gertrauden Berlin; University Magdeburg; Klinikum Offenbach; Frauenklinik München; University Heidelberg; Kliniken Essen Mitte; Charite Berlin; Helios Kliniken Berlin
| | - M Untch
- German Breast Group, Neu-Isenburg; Louisenkrankenhaus Düsseldorf; University Erlangen; University Duesseldorf; Bethanien-Kankenhaus Frankfurt; Klinikum Landshut; Eilenriedeklinik Duesseldorf; University Kiel; University Rostock; Roteskreuzklinikum Muenchen; Sankt Gertrauden Berlin; University Magdeburg; Klinikum Offenbach; Frauenklinik München; University Heidelberg; Kliniken Essen Mitte; Charite Berlin; Helios Kliniken Berlin
| |
Collapse
|
46
|
Loibl S, La De Haba J, von Minckwitz G, Morales S, Crespo C, Antón A, Carrasco E, Aktas B, Mehta K, Martin M. Phase III Trial Evaluating the Addition of Bevacizumab to Endocrine Therapy as First-Line Treatment for Advanced Breast Cancer: The GEICAM/GBG Lea Study. Safety Analysis. Ann Oncol 2012. [DOI: 10.1016/s0923-7534(20)32942-2] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022] Open
|
47
|
Otiv AS, Mehta K, Ali U, Nadkarni M. Sonographic measurement of renal size in normal indian children. Indian Pediatr 2012; 49:533-6. [DOI: 10.1007/s13312-012-0120-7] [Citation(s) in RCA: 19] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/02/2011] [Accepted: 10/05/2011] [Indexed: 10/28/2022]
|
48
|
Samra G, Mehta K. A profile of emergency readmissions to Department of Surgery, Victoria Hospital, Blackpool. BMC Proc 2012. [PMCID: PMC3426034 DOI: 10.1186/1753-6561-6-s4-p2] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022] Open
|
49
|
Kuo H, Mehta K, Yaparpalvi R, Hong L, Wu A, Mynampati D, Bodner W, Garg M, Kalnicki S. PO-234 DOSE OPTIMIZATION OF INTRA-VAGINAL BRACHYTHERAPY USING DIFFERENT MULTI-CHANNEL APPLICATORS. Radiother Oncol 2012. [DOI: 10.1016/s0167-8140(12)72200-4] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/28/2022]
|
50
|
Sinn B, von Minckwitz G, Denkert C, Eidtmann H, Darb-Esfahani S, Belau A, Kronenwett R, Holzhausen H, Mehta K, Loibl S. 8O_PR MUCIN-1 Protein and Mrna Expression in Breast Cancer Patients Treated with Neoadjuvant Chemotherapy. Ann Oncol 2012. [DOI: 10.1093/annonc/mds039] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|